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ABSTRACT 
Cell membrane is a barrier to be overcome for efficient delivery of therapeutics 
into a target site in cytoplasm or nucleus. The hydrophobic phospholipids are major 
components of the cell membrane that obstruct the transportation of therapeutics. 
Thus, various delivery systems, such as liposomes, nanoparticles and viral vectors, 
have been developed to transfer small molecules, peptides, proteins, and 
oligonucleotides across the membrane. 
Negatively charged phosphopeptides, oligonucleotides, and siRNAs have 
emerged as potential therapeutic agents. Phosphopeptides mimic phosphoproteins, 
which give on/off signal to many enzymes through interactions with protein kinases. 
For example, phosphopeptide pTyr-Glu-Glu-Ile (pYEEI) is an optimal peptide ligand 
for binding to the Src tyrosine kinase SH2 domain. Oligonucleotides have been 
introduced as antisense drugs to inhibit the translation of mRNA that transfers the 
coding information from genes. Small interfering RNA (siRNA)-based therapy has 
been also spotlighted since the discovery of RNA interference (RNAi) phenomenon. 
However, the cellular delivery of phosphopeptides, oligonucleotides, and siRNAs is a 
major obstacle despite many advantages of these compounds. Phosphopeptides 
contain negatively charged phosphate group, and/or negatively charged amino acids, 
such as glutamic acid or aspartic acid, in their sequences. Oligonucleotides and 
siRNAs are polymers composed of nucleosides, which are connected through 
negatively charged phosphodiester groups. These negatively charged molecules are 
hard to enter cancer cells by diffusion because cancer cell membranes are composed of 
negatively charged lipids. In addition, when a naked siRNA is administered in vivo, it 
  
does not show efficient cellular uptake in most mammalian cells and is quickly 
disappeared in the blood. Thus, developing carriers to improve the cellular uptake 
delivery of negatively charged cell-impermeable compounds has become a subject of 
major interest. Novel strategies are urgently needed to circumvent the problems 
associated with the delivery of these compounds. 
Cell-penetrating peptides (CPPs) have become one of the emerging vehicles for 
delivery of cargo drugs. CPPs are short hydrophilic or amphiphilic peptides that have 
plenty of positively charged amino acids, such as lysine or arginine, which can 
penetrate cell membranes. CPP-drug conjugates have been reported to help the cellular 
uptake of some drugs. Alternatively, they have been used as non-covalent drug 
delivery systems. 
CPPs have been investigated for improving the intracellular delivery of 
negatively-charged molecules. By physical interaction between positive charges in 
CPPs and negative charges in phosphopeptides, oligonucleotides, and siRNAs, the cell 
penetration could be improved. Among many CPPs, arginine-rich peptides have been 
the subject of major focus because it has been known that the guanidine group of 
arginine side chain shows better interaction with the negatively charged phospholipid 
in the cell membrane. Tryptophan is also a key amino acid found in CPPs that 
enhances the interaction of peptides with lipids in the cell membrane. 
Parang’s laboratory has previously shown that monocyclic CPPs containing 
alternative arginine and tryptophan have potential applications for drug delivery. 
Cyclic peptides have several benefits compared to linear peptides, such as stability 
against proteolytic enzymes and rigidness of structure. The rigidity of the structure can 
  
enhance the binding affinity of ligands toward receptors by reducing the freedom of 
possible structural conformations. Cyclic peptides are also present in nature and have 
been developed as therapeutics. Cyclosporin, gramicin S, polymoxin B, and 
daptomycin are well-known examples of cyclic peptides. Parang’s laboratory designed 
amphiphilic cyclic CPPs containing alternative tryptophan and arginine residues as the 
hydrophobic and positively charged residues, respectively. The peptides were efficient 
in improving the cellular delivery of anticancer and antiviral drugs. 
In this dissertation, we designed novel classes of amphiphilic cyclic peptides for 
improving the intracellular delivery of cell-impermeable phosphopeptides, and their 
antimicrobial activities were investigated. The hypothesis of this dissertation is that 
amphiphilic cyclic peptides, having positively charged arginines on one side of 
structures and hydrophobic tryptophan (or fatty acid) on the other side, can enhance 
intracellular drug delivery and/or act as antimicrobial agents having synergy with 
other antibiotics. 
In Manuscript I (Submitted to Angewandte Chemie International Edition), we 
designed amphiphilic bicyclic peptides as cellular delivery agents. The objective of 
this manuscript was to design a novel class of bicyclic CPPs containing two 
monocyclic peptides of tryptophan and arginine amino acids. Two bicyclic peptides 
[W5G]-(triazole)-[KR5] and [W5E]-(-Ala)-[KR5] were synthesized by conjugation of 
two monocyclic peptides using click chemistry and amide synthesis, respectively. A 
corresponding linear peptide, W5G-(triazole)-KR5, and a monocyclic peptide with a 
linear component, [W5G]-(triazole)-KR5, were synthesized as controls. Among all 
peptides, [W5E]-(-Ala)-[KR5] improved the cellular delivery of fluorescein-labeled 
  
phosphopeptide, F-GpYEEI by 19.3-fold. Confocal microscopy showed that the 
corresponding fluorescein-labeled bicyclic peptide F-[KW4E]-(-Ala)-[KR5] was 
localized in the cytosol and nucleus in human ovarian adenocarcinoma (SK-OV-3) 
cells. Studying the cellular uptake of F-[KW4E]-(-Ala)-[KR5] in the presence of 
endoycytosis inhibitors indicated that the clathrin- and caveolin-dependent 
endocytosis were the main pathways for cellular uptake. [W5E]-(-Ala)-[KR5] 
enhanced the intracellular uptake of fluorescein-labeled phosphopeptide, F-GpYEEI 
by 4.5- and 3.0-fold compared to those of well-known cell-penetrating peptides 
(CPPs), TAT and CR7, respectively. The bicyclic peptide was able to improve 
antiproliferative activity of doxorubicin by 20%. Thus, this manuscript suggests that 
amphiphilic bicyclic peptides containing tryptophan and arginine can be utilized as a 
new class of cell-penetrating peptides and potential cellular delivery tools. 
In Manuscript II (Submitted to Molecular Pharmaceutics), we investigated the 
role of fatty acylation and cyclization for intracellular transport of phophopepides in 
short-length polyarginine peptides Most of the reported arginine-rich CPPs to enhance 
intracellular drug delivery are linear peptides, and have more than seven arginines to 
retain cell penetrating properties. Herein, we synthesized penta and hexaarginine 
peptides (R5 and R6), and explored the effect of acylation and cyclization on the cell 
penetrating properties of the peptides. The fluorescence-labeled acylated cyclic 
peptide dodecanoyl-[R5] and linear peptide dodecanoyl-(R5) showed approximately 
13.7- and 10.2-fold higher cellular uptake than that of control 5(6)-carboxyfluorescein, 
respectively. The mechanism of the peptide internalization into cells was found to be 
energy-dependent endocytosis. The molecular transporter property of fatty acylated 
  
cyclic peptides was compared with those of fatty acylated linear peptide and 
nonacylated cyclic peptide using flow cytometry. The combination of acylation and 
cyclization (dodecanoyl-[R5]) enhanced intracellular delivery of a fluorescence-
labeled phosphopeptide (F′-GpYEEI) in human SK-OV-3 cancer cell line. 
Dodecanoyl-[R5] and dodecanoyl-[R6] enhanced the intracellular uptake of a 
fluorescence-labeled cell impermeable negatively charged phosphopeptide (F′-
GpYEEI) in human ovarian cancer cells (SK-OV-3) by 3.4-fold and 5.5-fold, 
respectively. The cellular uptake of F′-GpYEEI in the presence of hexadecanoyl-[R5] 
was 9.3- and 6.0-fold higher than that of in the presence of octanoyl-[R5] and 
dodecanoyl-[R5], respectively. A comparative FACS results showed that dodecanoyl-
[R5] enhanced the cellular uptake of the phosphopeptide by 1.4-2.5 fold higher than 
the corresponding linear peptide dodecanoyl-(R5) and those of representative CPPs, 
such as hepta-arginine (CR7) and TAT peptide. In this manuscript, we found that a 
combination of acylation by long chain fatty acids and cyclization on short arginine-
containing peptides can improve their cell-penetrating property, possibly through 
efficient interaction of rigid positively charged R and hydrophobic dodecanoyl moiety 
with the corresponding residues in the cell membrane phospholipids. 
In Manuscript III (to be submitted to Molecular Pharmaceutics), the 
antimicrobial activities of cyclic CPPs were investigated against multidrug resistant 
pathogens. Antimicrobial peptides and CPPs share similar structural features. Based 
on the intracellular delivery property of amphiphilic cyclic peptides in manuscript II, 
we synthesized several amphiphilic cyclic CPPs and their analogs, and investigated 
antibacterial activities against multidrug resistant pathogens. [R4W4] exhibited a 
  
potent antibacterial activity, exhibiting MIC value of 2.67 µg/mL against methicillin-
resistant Staphylococcus aureus (MRSA). Cyclic [R4W4] and the linear counterpart 
R4W4 exhibited MIC values of 42.8 and 21.7 µg/mL, respectively, against 
Pseudomonas aeruginosa. [R4W4] in combination with tetracycline enhanced the 
potency, by decreasing the MIC 4 fold (0.12 µg/mL), suggesting partial synergistic 
effect of the combination between [R4W4] and tetracycline against MRSA. Twenty-
four hour time-kill studies evaluating [R4W4] in combination with tetracycline 
demonstrated bactericidal activity against MRSA and E. coli. [R4W4] showed cell-
penetrating properties as expected, and exhibited more than 84% cell viability at 15 
µM (20.5 µg/mL) concentration against three different human cell lines. This study 
suggests that amphiphilic cyclic CPPs, when used in combination with antimicrobials 
could provide additional benefit to defeat multi-drug resistant pathogens. 
In summary, the studies in this dissertation provided insights and a deep 
understanding of applications of cyclic cell-penetrating peptides to enhance 
intracellular uptake of cargo drugs, and their antimicrobial activities as drug alone or 
combination with other antibiotics. Amphiphilic bicyclic peptides are the first reported 
bicyclic peptides as CPPs and molecular transporters. Acylated cyclic polyarginines 
showed that short polyarginines can be utilized as CPPs to have cell-penetrating 
properties by combining fatty acylation and cyclization. Moreover, this study provided 
a potential of amphiphilic cyclic CPPs as antimicrobial agents that their potency could 
be maximized by the combination with other antibiotics possibly through their drug 
delivery properties. Overall, these findings will be beneficial for the scientific 
  
community in academia and industry working in the area of designing molecular 
transporters of cell impermeable compounds, and cellular delivery.   
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Abstract 
Two bicyclic peptides [W5G]-(triazole)-[KR5] and [W5E]-(-Ala)-[KR5] 
composed of tryptophan and arginine residues were synthesized from monocyclic 
peptide building blocks and evaluated as cellular delivery agents. [W5G]-(triazole)-
[KR5] and [W5E]-(-Ala)-[KR5] containing triazole and β-alanine linkers improved 
the cellular delivery of fluorescein-labeled phosphopeptide, F-GpYEEI by 7.6 and 
19.3-fold, respectively, in human ovarian adenocarcinoma (SK-OV-3) cells. Confocal 
microscopy showed that the corresponding fluorescein-labeled bicyclic peptide F-
[KW4E]-(-Ala)-[KR5] was localized in the cytosol and nucleus. Studying the cellular 
uptake of F-[KW4E]-(-Ala)-[KR5] in the presence of endocytosis inhibitors indicated 
that the clathrin- and caveolin-dependent endocytosis were the main pathways for 
cellular uptake. The bicyclic peptide was able to improve antiproliferative activity of 
doxorubicin by 20%. These data suggest that amphiphilic bicyclic peptides containing 
tryptophan and arginine can be utilized as a new class of cell-penetrating peptides and 
potential cellular delivery tools.  
 
 4 
 
Cell-penetrating peptides (CPPs) have been studied as molecular transporters 
because of their cellular translocation properties.
[1]
 Covalent or non-covalent CPP-
drug conjugates have been designed to deliver cell-impermeable drugs, such as 
negatively charged phosphopeptides, oligonucleotides, and siRNAs.
[2]
 Various CPPs, 
such as TAT peptide, antennapedia, or polyarginines, have been used as molecular 
transporters for a wide range of molecular cargos.
[3,4]
 
Among CPPs, cyclic peptides take advantage of their higher serum stability 
compared to the linear counterparts.
[5]
 In addition, the presence of positively charged 
arginine and hydrophobic tryptophan amino acids were found to be critical due to their 
characteristic interactions with phospholipid membranes.
 [6–8]
 We have previously 
reported the development of homochiral cyclic peptides containing arginine and 
tryptophan [WR]4 and [WR]5 as nuclear-targeting CPPs.
[9]
 These monocyclic peptides 
were found to be effective tools as covalent and non-covalent molecular 
transporters.
[10,11]
 Our findings showed that in addition to the cyclic nature, the 
sequence of the peptide contributes significantly to the molecular transporter property 
of the peptide by keeping a balance between both hydrophobic and positively charged 
properties. 
To the best of our knowledge, bicyclic peptides have not been explored as CPPs 
and molecular transporters. We hypothesized that an amphiphilic bicyclic peptide 
containing two hydrophobic and positively charged cyclic peptides could act an 
alternative cellular delivery tool. Amphiphilic bicyclic peptides containing tryptophan 
and arginine amino acids and appropriate controls were synthesized and evaluated as 
 5 
 
CPPs and molecular transporters of a cell-impermeable negatively charged 
phosphopeptide. 
Two bicyclic peptides containing triazole and β-alanine linkers were synthesized 
to determine the effect of spacers in cellular delivery. First, a monocyclic peptide 
containing five arginine residues and one lysine azide [K(N3)R5] and a cyclic peptide 
[W5G(propargyl)] containing five tryptophans and one propargylglycine 
(G(propargyl)) were prepared and conjugated by click chemistry to generate [W5G]-
(triazole)-[KR5] containing a triazole linker (Figure 1a). Alternatively, bicyclic peptide 
[W5E]-(-Ala)-[KR5] was synthesized through linking two monocyclic peptides, 
[W5E] and (-Ala)-[KR5], through a -alanine (-Ala) spacer (Figure 1a) (See 
Supporting Information for experimental details). 
Furthermore, a corresponding linear peptide containing tryptophan and arginine 
residues, W5G-(triazole)-KR5, and a monocyclic peptide with a linear component, 
[W5G]-(triazole)-KR5, were synthesized as controls (Figure 1a) to determine the effect 
of the cyclic nature of the peptide. 
First, we examined the cytotoxicity of these peptides by MTS proliferation assay 
against human ovarian adenocarcinoma SK-OV-3 cell lines and human embryonic 
kidney HEK 293T cell lines. In both cancer and normal cell lines, all four peptides 
showed more than 80% cell viability at 10 M concentration (Supporting Information). 
Further cytotoxicity of [W5E]-(-Ala)-[KR5] was determined against a non-adherent 
cell line (human leukemia CCRF-CEM) after 24 h. The data showed that cell viability 
at 15 M peptide concentration was remained up to 88% in non-adherent CCRF-CEM 
 6 
 
cell line. Thus, a noncytotoxic concentration of 5-10 M was selected for further 
cellular uptake studies. 
To determine the ability of these amphiphilic peptides as molecular transporters, 
we used a negatively charged fluorescein-labeled phosphopeptide, F-GpYEEI (F = 
fluorescein), as a model cell-impermeable compound, which is known as a substrate of 
Src kinase SH2 domain.
[12,13]
 F-GpYEEI (5 M) was incubated in SK-OV-3 cells in 
the presence of these four peptides (10 M) for 1 h, and the cellular uptake was 
evaluated by flow cytometry. All four peptides enhanced the intracellular uptake of F-
GpYEEI. The cellular uptake of the phosphopeptide was increased 2.9-, 7.2-, 7.6-, and 
19.3-fold for linear W5G-(triazole)-KR5, monocyclic [W5G]-(triazole)-KR5, bicyclic 
[W5G]-(triazole)-[KR5], and bicyclic [W5E]-(-Ala)-[KR5], respectively. Thus, 
[W5E]-(-Ala)-[KR5] showed significantly higher cellular delivery of the 
phosphopeptide among all peptides (Figure 1b). These data showed that amphiphilic 
peptides containing tryptophan and arginine residues can enhance the transportation of 
a cell impermeable phosphopeptide. Moreover, cyclic nature of the peptide contributes 
significantly to the intracellular uptake since all the peptides containing one or two 
cyclic peptides showed higher molecular transporter property. In addition, the bicyclic 
peptide containing β-alanine linker, [W5E]-(-Ala)-[KR5], exhibited 2.5-fold higher 
uptake of the cell-impermeable phosphopeptide than that of bicyclic peptide [W5G]-
(triazole)-[KR5]. [W5E]-(-Ala)-[KR5] has a more flexible linker between two cyclic 
peptides. Thus, the nature and the length of the linker between two cyclic peptides are 
critical in generating an appropriate conformation for interaction with the cell 
membrane phospholipid and molecular transporter property of the compound. Thus, 
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bicyclic peptide [W5E]-(-Ala)-[KR5] was selected for further study and evaluation as 
a CPP. 
A corresponding fluorescein-labeled bicyclic peptide of [W5E]-(-Ala)-[KR5], F-
[KW4E]-(-Ala)-[KR5] (F = fluorescein) (Figure 2), was synthesized (See Supporting 
Information for experimental details) for cell permeability studies. SK-OV-3 cells 
were incubated with the fluorescein-labeled bicyclic peptide (10 M) for 1 h at 37 ⁰C. 
Confocal laser scanning microscope (CLSM) images showed that the fluorescein-
labeled bicyclic peptide was dispersed into the nucleus and cytosol (upper panel in 
Figure 2a), but no significant fluorescence was observed in the cells treated with 
fluorescein (FAM) alone under the same condition (lower panel in Figure 2a). The 
diffusion of fluorescence was observed in both cytoplasm and nucleus even though the 
punctate fluorescence was detected in FITC image. These data indicate that the 
bicyclic peptide is localized in cellular organelles possibly via endocytosis, and the 
peptide escapes from endosomes into the cytosol and nucleus. 
Flow cytometry analysis was further confirmed the cellular uptake of F-[KW4E]-
(-Ala)-[KR5]. SK-OV-3 cells were incubated for 1 h with the fluorescence-labeled 
peptides. The bicyclic peptide showed 2.9-fold more uptake when compared with 
fluorescein (FAM) (Figure 2b). The cellular uptake of the bicyclic peptide, F-
[KW4E]-(-Ala)-[KR5] was found to be 1.8-fold more in comparison to our previously 
reported monocyclic F-[W5R4K] peptide
[9]
 at 5 M concentration. These data indicate 
that the bicyclic peptide has higher cellular uptake when compared to the 
corresponding monocyclic peptide. Thus, this new bicyclic peptide could be used as 
an alternative CPP with more efficiency compared to the monocyclic peptide. 
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To examine the cellular uptake mechanism of F-[KW4E]-(-Ala)-[KR5], a 
temperature control assay was carried out at 4 °C to inhibit the energy-dependent 
endocytosis. The uptake of the bicyclic peptide was significantly reduced at 4 °C, 
indicating that the cellular uptake mechanism was dependent on the endocytosis 
(Figure 3a).
[14]
 To further confirm the energy-dependent cellular uptake of the bicyclic 
peptide, SK-OV-3 cells were incubated with sodium azide (10 mM) and 2-deoxy-D-
glucose (50 mM) for 1 h before and 1 h after adding the bicyclic peptide to induce 
ATP depletion. The result showed that there was inhibition by ATP depletion (Figure 
3a), which is consistent with the result of the temperature control assay at 4 °C, 
suggesting that endocytosis is the major pathway for the cellular uptake of the bicyclic 
peptide as shown for other systems.
[15]
 
The cellular uptake studies were also conducted in the presence of several 
endocytosis inhibitors, such as chloroquine, chlorpromazine, methyl -cyclodextrin, 
nystatin, and 5-(N-ethyl-N-isopropyl)amiloride (EIPA), to determine the specific 
endocytosis mechanism. SK-OV-3 cells were incubated with each inhibitor for 30 min 
before 1 h incubation with F-[KW4E]-(-Ala)-[KR5]. The results showed that only 
chlorpromazine and nystatin significantly reduced the cellular uptake of the bicyclic 
peptide (Figure 3b). Since chlorpromazine is a clathrin-dependent endocytosis 
inhibitor and nystatin blocks the lipid raft-caveolae endocytosis,
[16,17]
 we suggest that 
the cellular uptake mechanism of F-[KW4E]-(-Ala)-[KR5] is a clathrin- and 
caveolin-dependent endocytosis. These data indicate that the cellular uptake of the 
bicyclic peptide as a CPP follows a different pattern from that of cyclic peptide [WR]5, 
which showed endocytosis-independent cellular uptake.
[9]
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Bicyclic [W5E]-(-Ala)-[KR5] improved the uptake of F-GpYEEI by 19.3-fold as 
shown in Figure 1b. To evaluate the molecular transporter property of the bicyclic 
peptide compared to a number of other CPPs, such as linear polyarginine (CR7), TAT, 
and monocyclic peptide [WR]5, we carried out the cellular uptake assay using a 
fluorescein-labeled phosphopeptide, F-GpYEEI. Negatively charged F-GpYEEI was 
used as a model cell impermeable cargo. It was expected that the interaction between 
negatively charged phosphopeptides and positively charged bicyclic peptide could 
improve the cellular uptake of the phosphopeptide. For cellular uptake assay, we used 
a non-cytotoxic concentration of the bicyclic peptide (10 M). For comparative 
studies, F-GpYEEI was co-incubated using typical CPPs, such as linear polyarginine 
(CR7) and TAT peptides, and monocyclic [WR]5. After incubation of F-GpYEEI with 
or without the peptides in SK-OV-3 cells, FACS analysis was carried out to quantify 
the F-GpYEEI enhanced by CPPs. The intracellular uptake of F′-GpYEEI in the 
presence of the bicyclic peptide was enhanced by 4.5- and 3.0-fold higher than those 
of TAT and CR7 peptide, and 1.8-fold over [WR]5 cyclic CPP (See Supporting 
Information). Thus, [W5E]-(-Ala)-[KR5] was found to be a more efficient molecular 
transporter for the negatively-charged phosphopeptide compared to commonly used 
CPPs and our previous reported cyclic CPP.
[9]
 We have previously reported the 
binding affinity between monocyclic [WR]5 and the negatively charged 
phosphopeptide. Improved uptake in the presence of the bicyclic peptide could be due 
to the higher binding affinity with the phosphopeptide because of the presence of all 
positively-charged amino acids at one side and/or higher efficiency of the bicyclic 
peptide as a molecular transporter. 
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Next, an intracellular retention of a commercially available anticancer drug, 
doxorubicin (DOX), was determined in the presence and absence of the bicyclic 
peptide. SK-OV-3 cells were incubated with doxorubicin (5 M) and [W5E]-(-Ala)-
[KR5] (10 M) containing medium for 1 h. Then all compounds and media were 
removed, and fresh complete media was added and kept for 24 h. We found that the 
bicyclic peptide did not increase the cellular uptake of DOX compared to the free 
DOX after 1 h incubation. However, 1.7-fold higher retention of DOX was observed 
intracellularly in the presence of the bicyclic peptide after 24 h (Figure 4a). 
To determine whether [W5E]-(-Ala)-[KR5] can be exploited for the delivery of 
biologically relevant doses of DOX to cells, the antiproliferative activity of DOX was 
evaluated in SK-OV-3 cells in the presence and absence of the bicyclic peptide. The 
antiproliferative activity of DOX (1 M) in the presence of the [W5E]-(-Ala)-[KR5] 
(10 M) was improved by approximately 20% compared to that of DOX alone after 72 
h incubation (Figure 4b). An inhibitory effect on the cell proliferation of SK-OV-3 
cells suggests improved efficacy of DOX. [W5E]-(-Ala)-[KR5] alone did not show 
any toxicity in SK-OV-3 cells under similar conditions, suggesting that the higher 
antiproliferative is possibly related to the efflux inhibition of the drug in the presence 
of the bicyclic peptide or the time-delayed release of DOX from the endosome after 
cellular uptake. 
In conclusion, we report synthesized bicyclic peptides, [W5G]-(triazole)-[KR5] 
and [W5E]-(-Ala)-[KR5], as a new class of CPPs. To the best of our knowledge, this 
is the first bicyclic peptides as a cellular delivery tool. [W5E]-(-Ala)-[KR5] was 
internalized through a clathrin-mediated and lipid raft-caveolin-dependent endocytic 
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mechanism, and worked as a molecular transporter for delivery of a negatively-
charged phosphopeptide. [W5E]-(-Ala)-[KR5] also enhanced the retention of DOX in 
SK-OV-3 cells. Thus, an amphiphilic bicyclic peptide containing two monocyclic 
peptides can be used as a CPP and potential cellular delivery vehicle. 
 
Keywords: amphiphiles • bicyclic peptide • cell-penetrating • drug delivery • 
endocytosis 
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Figures 
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Figure 1. (a) The chemical structures of amphiphilic linear, monocyclic, and bicyclic 
peptides. (b) Cellular uptake of F’-GpYEEI (F’-PP, 5 M) in SK-OV-3 cells in the 
presence of bicyclic peptides (10 M) and their derivatives. 
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Figure 2. (a) Confocal Laser Scanning (CLSM) images of SK-OV-3 cells treated with 
bicyclic peptide F-[KW4E]-(-Ala)-[KR5] (10 M, upper) and FAM (10 M, lower) 
for 1 h; (b) FACS analysis of SK-OV-3 cells incubated with F-[KW4E]-(-Ala)-[KR5] 
(5 M) or F-[W5R4K] (5 M) for 1 h. 
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Figure 3. Cellular uptake of F’-[KW4E]-(-Ala)-[KR5] (5 M) in SK-OV-3 cells 
incubated (a) at 37 °C and 4 °C, (b) with 10 mM NaN3 and 50 mM 2-deoxy-D-glucose, 
and (c) with endocytic inhibitors (CQ: chloroquine; CPZ: chlorpromazine; MCD: 
methyl -cyclodextrin; NYS: nystatin; EIPA: 5-(N-ethyl-N-isopropyl) amiloride) 
analyzed by flow cytometry. 
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Figure 4. (a) The effect of [W5E]-(-Ala)-[KR5] (10 M) on cellular uptake of DOX 
(5 M) in SK-OV-3 cells. After 1 h incubation with compounds, the media were 
replaced with fresh complete media and kept for 24 h; (b) The antiproliferative assay 
of DOX (1 M) in the presence of [W5E]-(-Ala)-[KR5] (10 M) in SK-OV-3 cells for 
72 h. After 24 h incubation, the treatment was replaced by fresh media. The cells were 
kept in an incubator for 24-72 h. 
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Supporting Information 
Experimental Section 
1. General procedure 
Materials. The resins for peptide synthesis, coupling reagents, and Fmoc-protected 
amino acid building blocks were purchased from Chem-Impex International, Inc. 2-
(1H−Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) 
was purchased from Oakwood products, Inc. Other chemicals and reagents were 
purchased from Sigma-Aldrich Chemical Co. 
 
Solid-phase peptide synthesis. All reactions were carried out manually in a glass 
reaction vessel with a sintered glass frit by mixing under nitrogen bubbling at room 
temperature, unless otherwise stated. Generally, all linear and monocyclic peptides 
were synthesized by the Fmoc/tBu solid phase synthesis strategy, employing N-(9-
fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-L-amino acid building 
blocks, and head-to-tail cyclization method as described previously by us.
[9]
 Single 
amino acid loaded 2-chlorotrityl resins were used for conjugation with Fmoc-L-amino 
acid building blocks. HBTU and N,N-diisopropylethylamine (DIPEA) in N,N-
dimethylformamide (DMF) were used as coupling and activating reagents, 
respectively. Fmoc-deprotection at each step was carried out in the presence of 
piperidine in DMF (20%) followed by washing with DMF. The linear peptides were 
cleaved from the resins and the side chains were deprotected by shaking with freshly 
prepared cleavage cocktail of trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water 
(92.5/5/2.5, v/v/v) for 2-3 h. The crude peptides were filtered, and the resins were 
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washed again with 2-3 mL of cleavage cocktail. The crude peptides were precipitated 
and washed with cold diethyl ether.  
 
For cyclization, a cleavage cocktail, 2,2,2-trifluoroethanol (TFE)/acetic 
acid/dichloromethane (DCM) (2:1:7, v/v/v) was used for 1 h to cleave side-chain 
protected linear peptides from resins. The resins were filtered off, and the filtrate was 
repeatedly evaporated and dissolved in a small portion of DCM and hexane. The 
obtained side-chain protected linear peptides were kept in vacuum for overnight and 
used directly for the cyclization. Cyclization of linear peptides was carried out in the 
presence of a mixture of 1-hydroxy-7-azabenzotriazole (HOAT) and N,N-
diisopropylcarbodiimide (DIC) in anhydrous DMF/DCM for 24 h. The solvents were 
evaporated and the side-chain deprotection groups of cyclic peptide were removed by 
cleavage cocktails, TFA/thioanisole/1,2-ethanedithiol (EDT)/anisole (90:5:3:2, 
v/v/v/v) or TFA/TIS/water (92.5/5/2.5, v/v/v) for 2-3 h reaction. The crude 
monocyclic peptides were precipitated and washed with cold diethyl ether.  
The crude peptides were purified on a reversed-phase high pressure liquid 
chromatography (RP-HPLC) system using Shimadzu LC-8A preparative liquid 
chromatography on a Phenomenex Gemini C18 column (10 μm, 250 × 21.2 mm) with 
a gradient 0-100% of acetonitrile (CH3CN) containing 0.1% TFA (v/v) and water 
containing 0.1% (v/v) for 1 h with a flow rate between 9 to 18 mL/min at 214 nm 
wavelength. Purity of some compounds was confirmed by analytical HPLC using an 
RP-C18 column (Shimadzu Premier C18, 3 μm, 150 × 4.6 mm). The chemical 
structures of final products were confirmed by an AXIMA performance matrix-
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assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometer 
(Shimadzu Corporation). 
 
2. Synthesis of linear K(N3)R5. H-Arg(Pbf)-2-chlorotrityl resin (1389 mg, 0.5 mmol, 
0.36 mmol/g) was swelled in DMF for 30 min by N2. Fmoc-Arg(Pbf)-OH (1298 mg, 2 
mmol, 4 equiv) was coupled to the N-terminal of H-Arg(Pbf)-2-chlorotrityl resin, 
using HBTU (758 mg, 2 mmol, 4 equiv) and DIPEA (697 µL, 4 mmol, 8 equiv) in 
DMF (7 mL) by agitating the resin for 1 h using N2. After the coupling, the resin was 
washed with DMF, followed by Fmoc-deprotection. The subsequent three Fmoc-
Arg(Pbf)-OH couplings and one Fmoc-Lys(N3)-OH (789 mg, 2 mmol, 4 equiv) 
coupling was carried out in the same manner, respectively. The terminal Fmoc group 
was deprotected, followed by washing with DMF, DCM, and methanol. The crude N-
azido KR5 was cleaved by shaking with a freshly prepared cleavage cocktail, 
TFA/TIS/water (92.5:5:2.5, v/v/v, 15 mL) for 3 h, and purified by a method described 
in general procedure. K(N3)R5: HPLC (Rt)  = 9.30 min; MALDI-TOF (m/z): 
C36H72N24O7 calcd. 952.6016; found 952.9263 [M]
+
.  
 
3. Synthesis of linear W5G(propargyl). H-Trp(Boc)-2-chlorotrityl resin (769 mg, 0.6 
mmol, 0.78 mmol/g) was swelled using DMF, and coupled with Fmoc-Trp(Boc)-OH 
(1264 mg, 2.4 mmol, 4 equiv) using HBTU (910 mg, 2.4 mmol, 4 equiv) and DIPEA 
(836 µL, 4.8 mmol, 8 equiv) with DMF (10 mL) for 1 h, followed by Fmoc-
deprotection. The coupling and deprotection cycle was repeated 3 more times 
followed by coupling with Fmoc-L-Gly(propargyl)-OH (804 mg, 2.4 mmol, 4 equiv) 
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using HBTU (910 mg, 2.4 mmol, 4 equiv), and DIPEA (836 μL, 4.8 mmol, 8 equiv) in 
DMF (10 mL). The crude W5G(propargyl) was obtained by TFA/TIS/water cleavage 
and precipitation using cold diethyl ether as described above. W5G(propargyl): 
1
H 
NMR (DMSO-d6, 300 MHz,  ppm): 12.63 (s, 1H, COOH), 10.60-10.89 (m, 5H, NH 
Trp), 7.94-8.34 (m, 5H, NH), 6.84-7.68 (m, 25H, ArH), 4.42-4.74 (m, 6H, αCH Trp 
and Gly(propargyl)), 2.85-3.22 (m, 10H βCH2 Trp), 2.56-2.67 (m, 2H, βCH2 
Gly(propargyl)), 1.88 (m, 1H, CH Gly(propargyl)), 1.00 (d, J = 6.5, 2H, NH2); HPLC 
(Rt) = 14.00 min; MALDI-TOF (m/z): C60H57N11O7 calcd. 1043.4442; found 
1066.6016 [M + Na]
+
, 1082.1667 [M + K]
+
. 
 
4. Synthesis of monocyclic peptides. The synthetic procedure is same as the linear 
peptide except the cleavage and additional cyclization step as described in the general 
procedure. As a representative example, the synthesis of [W5G(propargyl)] is 
described here (Scheme S1). The side-chain protected linear W5G(propargyl) was 
synthesized as described above. The side chain protected linear peptide was cleaved 
from the resin with TFE/acetic acid/DCM mixture and cyclized in the presence of 
HOAT (326 mg, 2.4 mmol, 4 equiv) and DIC (371 μL, 2.4 mmol, 4 equiv) in dilute 
anhydrous DMF/DCM (5:1, v/v, 250 mL) under N2 with stirring for 24 h. 
[W5G(propargyl)]: 
1
H NMR (DMSO-d6, 300 MHz,  ppm): 10.66-10.84 (m, 5H, NH 
Trp), 7.90-8.31 (m, 6H, NH), 6.86-7.55 (m, 25H, ArH), 4.01-4.33 (m, 5H, αCH Trp), 
3.70-3.70(s broad, 1H, αCH Gly(propargyl)), 2.98-3.23 (m, 10H βCH2 Trp), 2.54-2.65 
(m, 2H, βCH2 Gly(propargyl)), 1.75 (s, 1H, CH Gly(propargyl)); HPLC (Rt) = 28.30 
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min; MALDI-TOF (m/z): C60H55N11O6 calcd. 1025.4337; found 1048.1293 [M + 
Na]
+
, 1064.1329 [M + K]
+
. 
[K(N3)R5]: 
1
H NMR (DMSO-d6, 300 MHz,  ppm): 7.81-8.10 (m, 6H, NH), 6.88-7.24 
(s broad, 20H, NH guanidinium), 4.10-4.34 (m, 6H, αCH Arg and Lys), 3.18-3.35(m, 
10H, CH Arg), 1.82-1.88 (m, 12H βCH2 Arg and Lys), 1.40-1.60 (m, 16H, CH2 Arg 
and ,,CH2 Lys); HPLC (Rt) = 9.20 min; MALDI-TOF (m/z): C36H70N24O6 calcd. 
934.5910; found 935.2969 [M + H]
+
. 
[W5E]: HPLC (Rt) = 24.00 min; 
1
H NMR (DMSO-d6, 300 MHz,  ppm): 12.00 (s, 1H, 
COOH), 10.70-10.85 (m, 5H, NH Trp), 7.92-8.25 (m, 6H, NH), 6.90-7.60 (m, 25H, 
ArH), 4.18-4.32 (m, 5H, αCH Trp), 3.95-4.05 (m, 1H, αCH Glu), 2.90-3.13 (m, 10H 
βCH2 Trp), 2.65-2.77 (m, 4H, β,γ CH2 Glu); MALDI-TOF (m/z): C60H57N11O8 calcd. 
1059.4392; found 1082.2554 [M + Na]
+
, 1098.2372 [M + K]
+
. 
(-Ala)-[KR5]: HPLC (Rt) = 9.28 min; MALDI-TOF (m/z): C39H77N23O7 calcd. 
979.6376; found 980.4063 [M + H]
+
.  
The synthetic Schemes for [W5G(propargyl)], [W5E], [K(N3)R5], and (-Ala)-[KR5] 
are depicted in Schemes S1-S4, respectively. 
 
5. Conjugation of linear or monocyclic peptides by click chemistry. In general, the 
alkyne (1 equiv) and the azide (1 equiv) were dissolved in methanol/water. To this 
solution, pentahydrated copper sulphate (1 equiv), copper powder (Cu, 10 equiv), 
sodium ascorbate (10 equiv), and DIPEA (2 equiv) were added. The reaction mixture 
was stirred at room temperature under N2 and monitored by MALDI-TOF mass 
spectra. As a representative example, the synthesis of [W5G]-(click)-[KR5] is 
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described here (Scheme S5). [W5G(propargyl)] (7.00 mg, 0.0068 mmol, 1 equiv) and 
[K(N3)R5] (6.36 mg, 0.0068 mmol, 1 equiv) were dissolved in CH3OH/H2O (1:1, v/v, 
2 mL), and CuSO4.5H2O (1.7 mg, 0.0068 mmol, 1 equiv), Cu (4.32 mg, 0.068 mmol, 
10 equiv), sodium ascorbate (13.47 mg, 0.068 mmol, 10 equiv) and DIPEA (2.26 µL, 
0.013 mmol, 2 equiv) were added, and the mixture was stirred for 3 h. The mixture 
was filtered and the filtrate was dried using rotatory evaporator. The crude peptide 
[W5G]-(triazole)-[KR5] was purified using a preparative RP-HPLC and lyophilized to 
give 3 mg fluffy brown product. [W5G]-(triazole)-[KR5]: Yield 22% (fluffy brown 
solid 3 mg); 
1
H NMR (DMSO-d6, 300 MHz,  ppm): 10.69-10.92 (m, 5H, NH Trp), 
7.98-8.36 (m, 12H, NH), 6.77-7.74 (m, 46H, ArH and NH guanidinium), 4.00-4.40 
(m, 6H, αCH Trp and Gly(propargyl)), 3.58-3.95 (broad peak, 6H, αCH Arg and Lys), 
2.73-3.29 (m, 24H, βCH Arg and εCH Lys, βCH Trp and Gly(propargyl)), 1.25-1.96 
(m, 26H, β,γCH Arg and β,γ,δCH Lys). HPLC (Rt) = 10.60 min; MALDI-TOF (m/z): 
C96H125N35O12 calcd. 1960.0247; found 1961.7063 [M + H]
+
. 
[W5G]-(triazole)-KR5: Yield 26% (brown solid, 3.5 mg); HPLC (Rt) = 10.30 min; 
MALDI-TOF (m/z): C96H127N35O13 calcd. 1978.0353; found 1979.7148 [M + H]
+
.  
W5G-(triazole)-KR5: Yield 15% (brown solid, 4.0 mg); HPLC (Rt) = 10.30 min; 
MALDI-TOF (m/z): C96H129N35O14 calcd. 1996.0458; found 1996.7783 [M]
+
. 
 
6. Conjugation of monocyclic peptides by peptide bond. The dry powdered 
monocyclic peptides, [W5E] (12.7 mg, 0.012 mmol, 1 equiv) and (-Ala)-[R5K] 
(11.8mg, 0.012 mmol, 1 equiv), were added to 5 mL glass vial and dissolved in 
anhydrous DMF (1 mL) using magnetic bead with stirring at room temperature under 
 24 
 
N2 gas. The coupling and activating reagents, 1-hydroxybenzotriazole (HOBT, 4.21 
mg, 0.031 mmol, 2.6 equiv), (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP, 8.11 mg, 0.015 mmol, 1.3 equiv), and DIPEA (16.70 
μL, 0.096 mmol, 8 equiv) were added. The mixture was stirred for 1 h. After 1 h 
reaction, the bicyclic peptide was precipitated using cold diethyl ether and separated 
by centrifugation. The crude peptide was purified by RP-HPLC as described above 
(Scheme S6). [W5E]-(-Ala)-[KR5]: Yield 15% (white fluffy solid, 3.70 mg); 
1
H 
NMR (DMSO-d6, 300 MHz, δ ppm): 10.70-10.90 (m, 5H, NH Trp), 7.84-8.30 (m, 
14H, NH), 6.80-7.84 (m, 45H, ArH and NH, NH2 Arg), 4.14-4.37 (m, 5H, αCH Trp), 
3.97-4.16 (m, 7H, αCH Arg and Glu), 3.35-3.57 (m, 4H, βCH β-Ala and εCH Lys), 
2.90-3.20 (m, 10H, βCH Trp), 2.20-2.35 (m, 6H, β,γ CH Glu and αCH β-Ala), 2.52-
2.65 (m, 10H, δCH Arg), 1.75-1.93 (m, 12H, βCH Arg and Lys), 1.52-1.72 (m, 14H, 
γ,δCH Lys and γCH Arg); HPLC (Rt) = 32.30 min; MALDI-TOF (m/z): 
C99H132N34O14 calcd. 2021.0662; found 2022.6672 [M + H]
+
, 2043.5676 [M + Na]
+
. 
 
7. Synthesis of fluorescein-labeled monocyclic peptide (F-[KW4E]). H-Trp-(Boc)-
2-chlorotrityl chloride resin (0.3 mmol, 384 mg, 0.78 mmol/g) was swelled in DMF 
for 30 min under N2. Fmoc-Trp(Boc)-OH (632 mg, 1.2 mmol, 4 equiv) was coupled to 
N-terminal the resin using HBTU (455 mg, 1.2 mmol, 4 equiv) and DIPEA (418 μL, 
2.4 mmol, 8 equiv) in DMF (12 mL) by agitating the resin for 1 h. After completion of 
the coupling, the resin was washed with DMF (20 mL × 3) followed by Fmoc-
deprotection with piperidine in DMF (20% v/v) and again washed with DMF (20 mL 
× 3). The subsequent amino acids, Fmoc-Glu(OtBu)-OH (511 mg, 1.2 mmol, 4 equiv), 
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Fmoc-Trp(Boc)-OH, Fmoc-Trp(Boc)-OH, (Dde)-Lys(Fmoc)-OH (Dde: N-(1-(4,4-
dimethyl-2,6-dioxocyclohexylidene)ethyl)) (639 mg, 1.2 mmol, 4 equiv) and Fmoc-β-
Ala-OH (374 mg, 1.2 mmol, 4 equiv) were coupled in a similar manner, followed by 
each cycle of deprotection of Fmoc group after each coupling. Then a mixture of 5(6)-
carboxyfluorescence diisobutyrate (CFDI, 465 mg, 0.9 mmol, 3 equiv), 1-hydroxy-7-
azabenzotriazole (HOAT, 122 mg, 0.9 mmol, 3 equiv), 7-azabenzotriazol-1-yl-
oxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP, 469 mg, 0.9 mmol, 3 
equiv), and DIPEA (314 μL, 1.8 mmol, 6 equiv) in anhydrous DMF/DCM (5:1 v/v, 12 
mL) was added to the resin-bound linear peptide. The coupling reaction was carried 
out for 3 h at room temperature, and the resin was washed with DMF (20 mL × 3). 
The Dde protection at N-terminal was deprotected by agitating with hydrazine 
monohydrate in DMF (2% v/v, 15 mL × 3, 5 min). The CFDI protection was 
deprotected by incubating peptidyl resin with 20% piperdine in DMF (15 mL × 2, 10 
min. each) with final washing with DMF (20 mL × 3). Finally, the side chain protected 
peptide was cleaved from the resin by shaking the resin with a mixture of TFE/acetic 
acid/DCM (2:1:7, v/v/v, 50 mL) for 1 h. The solution was evaporated, and the residue 
was dried overnight in a vacuum. The crude peptide was used directly for the 
cyclization under a dilute condition with DMF/DCM (5:1, v/v, 250 mL), using HOAT 
(163 mg, 1.2 mmol, 4 equiv) and DIC (185 μL, 1.2 mmol, 4 equiv), and stirred for 24 
h under nitrogen atmosphere. After cyclization, the solvent was evaporated, and the 
side-chain deprotection was carried out by the addition of cleavage cocktail, 
TFA/thioanisole/EDT/anisole (90:5:3:2, v/v/v/v, 15 mL) for 2 h. The crude bicyclic 
peptide was precipitated and purified as describe above. The synthetic method of F-
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[KW4E] is presented in Scheme S7. F-[KW4E]: 
1
H NMR (DMSO-d6, 300 MHz, δ 
ppm): 11.58 (s, 1H, COOH), 10.62-10.92 (m, 4H, NH Trp) 7.80-8.26 (m, 8H, NH), 
6.44-7.66 (m, 29H, ArH), 5.75 (s, 2H, OH), 4.10-4.45 (m, 4H, αCH Trp), 4.92-4.06 
(m, 2H, αCH Glu and Lys), 2.58-3.19 (m, 8H, βCH Trp), 1.45-2.30 (m, 16H, α,βCH β-
Ala, β,γCH Glu, and β,γ,δ,εCH Lys; HPLC (Rt) = 18.20 min; MALDI-TOF (m/z): 
C79H74N12O15, calcd. 1430.5397; found 1469.4227 [M + K]
+
. 
 
8. Synthesis of fluorescein-labeled bicyclic peptide (F-[KW4E]-(-Ala)-[KR5]). 
The dry powdered fluorescein-labeled cyclic peptide F-[KW4E] (8.9 mg, 0.0062 
mmol, 1 equiv), 1-hydroxybenzotriazole (HOBT, 2.16 mg, 0.016 mmol, 2.6 equiv), 
and PyBOP (4.19 mg, 0.080 mmol, 1.3 equiv) were dissolved in DMF (1.5 mL). 
DIPEA (8.53 μL, 0.049 mmol, 8 equiv) was added dropwise with stirring using 
magnetic bead under N2 condition for 10 min. to preactivate COOH group of glutamic 
acid followed by dropwise addition of a solution of cyclic peptide (-Ala)-[KR5] (6.00 
mg, 0.0062 mmol, 1 equiv) in DMF (0.5 mL) (Scheme S8). The reaction was 
monitored by MALDI-TOF, showing completion of the reaction after 40 min. The 
crude fluorescein-labeled bicyclic peptide was precipitated by adding cold diethyl 
ether. The crude peptide was purified using RP-HPLC method described above. F-
[KW4E]-(-Ala)-[KR5]: HPLC (Rt) = 10.30 min; MALDI-TOF (m/z): 
C118H149N35O21, calcd. 2392.1667; found 2393.7971 [M + H]
+
.  
 
9. Cell culture. Human ovarian carcinoma cell line SK-OV-3, human leukemia cell 
line CCRF-CEM, and human embryonic kidney cell line HEK 293T were purchased 
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from American Type Culture Collection. The cells were grown in eagle’s minimum 
essential medium (EMEM) for SK-OV-3 and HEK 293T, and RPMI-1640 medium 
(ATCC, Manassas, VA) for CCRF-CEM, supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin solution (10,000 units of penicillin and 10 mg 
of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2 at 37 °C. 
 
10. Confocal laser scanning microscopy (CLSM) 
10.1. Cellular uptake of F-[KW4E]-(-Ala)-[KR5] in SK-OV-3. SK-OV-3 cells 
were seeded with complete EMEM on coverslips in 6-well plate (1 × 10
5
 cells/well) 
and kept until 50% confluency. The media were removed and cells were incubated 
with 10 M F-[KW4E]-(-Ala)-[KR5] in Gibco®  Opti-MEM®  I reduced serum 
medium (Life Technologies, Grand Island, NY) for 1 h at 37 ⁰C. Then cells were 
washed with 1X phosphate buffered saline with calcium and magnesium (PBS
+
) three 
times. The coverslips were mounted on microscope slides, and images were obtained 
using Carl Zeiss LSM 700 system with a 488 nm argon ion laser excitation and a BP 
505-530 nm band pass filter. 
 
11. Flow cytometry 
11.1. Cellular uptake of fluorescein-labeled bicyclic peptide. SK-OV-3 cells were 
grown in 6-well plates (2 × 10
5
 cells/well) with complete EMEM media prior 24 h to 
add F-[KW4E]-(-Ala)-[KR5]. The 1 mM of fluorescein-labeled bicyclic peptide stock 
solution was prepared in water and diluted in Gibco®  Opti-MEM®  I reduced serum 
medium to generate 5 M concentration. The culture media were removed from 6-well 
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plates, and the prepared 5 M fluorescein-labeled bicyclic peptide solution was added. 
After 1 h incubation, trypsin-EDTA solution was added to detach cells from plate’s 
surface and remove cell surface binding peptides. After 5 min of treatment with 
trypsin-EDTA, a portion of complete media was added to stop the activity of trypsin. 
The cell lines were collected and centrifuged at 2500 rpm. Then they were washed 
twice using PBS without calcium and magnesium, and prepared in FACS buffer for 
cell sorting. Finally, the cells were analyzed by BD FACSCalibur™ or FACSVerse™ 
flow cytometer using FL1/FITC channel. The data collection was based on the mean 
fluorescence signal for 10,000 cells. All assays were carried out in triplicate. 5(6)-
Carboxyfluorescein (FAM) was used as the negative control. 
 
11.2. Mechanistic study of cellular uptake by removing energy sources. To 
examine the cellular uptake mechanism F-[KW4E]-(-Ala)-[KR5] at low temperature, 
the uptake assay was carried out at 4 °C to inhibit the energy-dependent cellular 
uptake. SK-OV-3 cells were preincubated at 4 °C for 15 min, and incubated with the 
fluorescein-labeled bicyclic peptide for 1 h at 4 °C. Cells were collected and assessed 
with the same protocol described in cellular uptake of fluorescein-labeled bicyclic 
peptide. The data collected at 37 °C were used for control. For the ATP-depletion 
assay, cells were incubated with 10 mM sodium azide and 50 mM 2-deoxy-D-glucose 
for 1 h before adding the fluorescein-labeled bicyclic peptide. During 1 h incubation, 
the 50 M of fluorescein-labeled bicyclic peptide was prepared in the Opti-MEM®  I 
reduced serum medium in the presence of 10 mM sodium azide and 50 mM 2-deoxy-D-
glucose. Then the cells were incubated with this solution for 1 h. The protocol for 
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sample preparation and flow cytometry analysis was same with the protocol described 
in cellular uptake of fluorescein-labeled bicyclic peptide. 
 
11.3. Cellular uptake pathway study using endocytosis inhibitors. The cellular 
uptake studies were also conducted in the presence of several endocytosis inhibitors. 
Chloroquine (100 M), chlorpromazine (30 M), methyl -cyclodextrin (2.5 mM), 
nystatin (50 g/mL), and 5-(N-ethyl-N-isopropyl)amiloride (EIPA, 50 M) were used. 
SK-OV-3 cells were incubated with each inhibitor for 30 min before 1 h incubation 
with F-[KW4E]-(-Ala)-[KR5]. The protocol for sample preparation and flow 
cytometry analysis was same with the protocol described in cellular uptake of 
fluorescein-labeled bicyclic peptide. 
 
12. Cytotoxicity assay by MTS assay. MTS proliferation assays were performed 
against two human cancer cell lines (SK-OV-3 and CCRF-CEM) and one human 
normal cell line (HEK 293T). Cells were seeded on 96-well plates (5 × 10
3
 cells for 
SK-OV-3, 1 × 10
5
 cells for CCRF-CEM, and 1 × 10
4
 cells for HEK 293T) and  
incubated with 100 L of complete media for overnight. The various concentrations 
(0– 600 M) of the bicyclic peptide solution (10 L) were added to cells, and kept at 
37 C with 5% CO2 for 24 h. Then 20 L of CellTiter 96 aqueous solution were added 
on each well and incubated at 37 C with 5% CO2 for 1-4 h. The absorbance was 
obtained at 490 nm using microplate reader. The cells without any peptide were used 
as control.  
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We carried out cytotoxic assay of all peptides against two adherent cell lines (SK-OV-
3 and HEK 293T) using above protocol (Figure S1). In case of [W5E]-(-Ala)-[KR5], 
we examined further cytotoxicity against non-adherent cell line (human leukemia 
CCRF-CEM). The result of cytoxicity against CCRF-CEM was presented at Figure 
S2. 
 
13. Cellular uptake of a phosphopeptide, F-GpYEEI in the presence of peptides. 
To evaluate and compare the molecular transporter property of the bicyclic peptides, 
their analogues, and other representative CPPs ([WR]5, TAT, CR7), the following 
procedure was employed. SK-OV-3 cells were seeded in 6-well plates (2 × 10
5
 
cells/well) and grown with complete EMEM media for overnight. A fluorescein-
labeled phosphopeptide, F-GpYEEI (5 M), and synthesized peptides (10 M) were 
premixed in OPTI-MEM I®  reduced serum medium at room temperature for 30 min. 
Then the cells were incubated with the premixed solution at 37 C with 5% CO2 for 1 
h. The sample preparation for FACS analysis was carried out with the same protocol 
described for cellular uptake for fluorescein-labeled bicyclic peptide. DMSO and F-
GpYEEI were used as a negative control (Figure S3). 
 
14. Cellular uptake of doxorubicin (DOX). DOX uptake in the presence of the 
bicyclic peptide was performed in SK-OV-3 cells. Dox (5 M) and the bicyclic peptide 
(10 M) were premixed in OPTI-MEM I®  reduced serum medium. The premixed 
solution was added to cells and kept for 1 h at 37 C with 5% CO2. Then the media 
were replaced by fresh complete media and incubated for 24 h. The sample 
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preparation and FACS analysis were the same as described above except using 
FL2/PE channel. 
 
15. Antiproliferative assay of doxorubicin in the presence of the bicyclic peptide. 
The antiproliferative activity of DOX alone and in the presence of [W5E]-(β-Ala)-
[KR5] against SK-OV-3 cells was determined by MTS assay. All cells were plated 
overnight in 96-well plates with a density of 5000 cells per well in 0.1 mL of 
appropriate growth medium at 37 °C. DOX alone (1 µM) or a combination of DOX (1 
µM) and [W5E]-(β-Ala)-[KR5] (10 µM) were incubated with the cells for 24 h. After 24 
h incubation, the treatment was replaced by fresh media. The cells were kept in an 
incubator for 24-72 h. The cells without compounds were included in each experiment 
as controls. After each incubation period of time, 20 µL of MTS solution was added 
and incubated for 2 h. The absorbance of the formazan product was measured at 490 
nm using a microplate reader. The percentage of cell viability was calculated as (OD 
value of untreated cells − OD value of treated cells)/OD value of untreated cells × 
100%. 
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Figures for supporting information 
 
Figure S1. Cytotoxicity of amphiphilic peptides in human ovarian adenocarcinoma 
SK-OV-3 and human embryonic kidney HEK 293T cells after 24 h incubation. 
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Figure S2. Cytotoxicity of [W5E]-(-Ala)-[KR5] against human leukemia CCRF-
CEM cell after 24 h incubation. 
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Figure S3. Cellular uptake of F-GpYEEI (F-PP, 5 µM) in SK-OV-3 cells in the 
presence of cell-penetrating peptides (10 µM). The sequences of CR7 and TAT are 
CRRRRRRR-NH2 and YGRKKRRQRRR-NH2, respectively. 
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Schemes for supporting information 
 
Scheme S1. The synthesis of monocyclic peptide [W5G(propargyl)]. 
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Scheme S2. The synthesis of monocyclic peptide [W5E]. 
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Scheme S3. The synthesis of monocyclic peptide [K(N3)R5]. 
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Scheme S4. The synthesis of monocyclic peptide (β-Ala)-[KR5]. 
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Scheme S5. The conjugation of two monocyclic peptides for the synthesis of [W5G]-
(triazole)-[KR5] peptide. 
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Scheme S6. The conjugation of two monocyclic peptides for the synthesis of [W5E]-
(β-Ala)-[KR5] peptide. 
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Scheme S7. The synthesis of monocyclic F-[KW4E] peptide. 
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Scheme S8. The synthesis of fluorescein-labeled bicyclic peptide F-[KW4E]-(β-Ala)-
[KR5]. 
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ABSTRACT 
The majority of the reported arginine-rich cell-penetrating peptides (CPPs) for the 
enhanced delivery of drugs are linear peptides. Moreover, they are usually composed 
of more than seven arginine residues to retain the cell penetration properties. Herein, 
we synthesized a class of eight polyarginine peptides containing 5 and 6 arginines 
namely R5 and R6. We further explored the effect of acylation with long chain fatty 
acids (i.e., octanoic acid, dodecanoic acid, hexadecanoic acid), and cyclization of 
amino acids on the cell penetrating properties of the peptides. The fluorescence-
labeled acylated cyclic peptide dodecanoyl-[R5] and linear peptide dodecanoyl-(R5) 
showed approximately 13.7- and 10.2-fold higher cellular uptake than that of control 
5(6)-carboxyfluorescein, respectively. The mechanism of the peptide internalization 
into cells was found to be energy-dependent endocytosis. The molecular transporter 
ability of fatty acylated cyclic peptides was evaluated using a flow cytometry method. 
Dodecanoyl-[R5] and dodecanoyl-[R6] enhanced the intracellular uptake of a 
fluorescence-labeled cell impermeable negatively charged phosphopeptide (F′-
GpYEEI) in human ovarian cancer cells (SK-OV-3) by 3.4-fold and 5.5-fold, 
respectively. The cellular uptake of F′-GpYEEI in the presence of hexadecanoyl-[R5] 
was 9.3- and 6.0-fold higher than that of in the presence of octanoyl-[R5] and 
dodecanoyl-[R5], respectively. A comparative FACS results showed that dodecanoyl-
[R5] enhanced the cellular uptake of the phosphopeptide by 1.4-2.5 fold higher than 
the corresponding linear peptide dodecanoyl-(R5) and those of representative CPPs, 
such as hepta-arginine (CR7) and TAT peptide. Our findings showed that a 
combination of acylation by long chain fatty acids and cyclization on short arginine-
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containing peptides can improve their cell-penetrating property, possibly through 
efficient interaction of rigid positively charged R and hydrophobic dodecanoyl moiety 
with the corresponding residues in the cell membrane phospholipids. 
 
Keywords: Acylation, Cyclic Peptide, Cyclization, Drug Delivery, Polyarginine.  
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INTRODUCTION 
Polyarginine peptides are known as one of the widely used classes of cell-
penetrating peptides (CPPs) and cellular delivery tools.
1
 It has been reported that the 
presence of the guanidine group in the side chain of arginine plays a key role for 
improved ability of arginine-rich peptides to cross the cell membrane.
2,3
 Various 
systematic structural investigations have been performed to determine the required 
number of arginine residues and the length of the peptide for the optimization of 
cellular uptake.
2,4
 Short polyarginine peptides containing less than six arginine 
residues did not exhibit significant cellular uptake in several previously reported 
investigations.
2,4,5
 Thus, the presence of more than six arginine residues in the 
structure of polyarginine peptides is critical for their efficient cell-penetrating 
functions. 
On the other hand, several investigations were conducted to increase the cellular 
uptake of polyarginines by attaching the fatty acid to the N-terminal of the peptide. It 
has been previously reported that the acylation of the N-terminal by fatty acids can 
facilitate the intracellular uptake of polyarginines.
6–8
 For instance, Katayama et al. 
synthesized acylated octa-arginines and discovered that the introduction of 
hydrophobic fatty acid enhanced the intracellular uptake of octa-arginine peptide and 
its conjugated ubiquitin.
8
 Furthermore, Lee et al. designed a class of lipopeptides 
carrying 7-15 arginine residues. Among them, myristoylated-hendeca-arginine 
(C14R11) was found to be the most efficient cell-penetrating peptide.
7
 However, the 
fatty acylated polyarginine peptides that contain 7-15 arginine residues can potentially 
cause toxicity, and they can be easily degraded by proteases. 
 48 
 
Moreover, linear peptides carrying L-form are not stable in serum and therefore 
have a limited application for in vivo studies.
9
 Replacing L-form amino acids with D-
form to improve the peptide stability leads to high cost production. On the other hand, 
cyclic peptides show more proteolytic stability than linear counterparts. Thus, the 
synthesis and development of cyclic CPPs containing short amino acid sequence with 
less toxicity is desired. 
Herein, we designed acylated cyclic polyarginine peptides (ACPPs) containing 
five arginine residues and investigated their ability as cell-penetrating peptides. We 
compared ACPPs with a corresponding acylated linear polyarginine peptide (ALPP) 
and a nonacylated cyclic polyarginine as controls. We hypothesize that the 
combination of acylation and cyclization of short polyarginine peptides having less 
than six arginine residues will increase the intracellular uptake and can generates 
peptides with molecular transporter properties. For convenience, square brackets [ ] 
and parentheses ( ) were used to represent cyclic and linear peptides, respectively. 
 
EXPERIMENTAL SECTION 
Peptide Synthesis. All peptides were synthesized by Fmoc/tBu solid-phase peptide 
synthesis strategy either manually or using Rainin PS3™ synthesizer (Protein 
Technologies Inc.). Manual reactions were carried out in a glass reaction vessel with a 
sintered glass frit by mixing under nitrogen bubbling at room temperature. Fmoc-L-
amino acid building blocks, fatty acids, and single Arg(Pbf) loaded 2-chlorotrityl resin 
were used as starting materials. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU), hydroxybenzotriazole (HOBT), and N,N-
 49 
 
diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were used as 
coupling and activating reagents, respectively for manual synthesis. In case of using 
peptide synthesizer, 0.4 M N-methylmorpholine in DMF was used instead of DIPEA. 
Piperidine in DMF (20%) was employed to deprotect Fmoc group at each step. 
To cleave the linear peptide from the resin, a mixture of trifluoroacetic acid 
(TFA)/triisoproylsilane (TIS)/water (92.5/5/2.5, v/v/v) was used. However, in the 
synthesis of cyclic peptides, the side chain protected linear peptides were first cleaved 
from the resin by using a cleavage cocktail, containing 2,2,2-trifluoroethanol 
(TFE)/acetic acid/dichloromethane (DCM) (2:1:7, v/v/v). Cyclization reaction was 
performed by employing a mixture of 1-hydroxy-7-azabenzotriazole (HOAT) and 
N,N-diisopropylcarbodiimide (DIC) in anhydrous DMF/DCM for 12 h. After solvent 
evaporation, the peptide was deprotected and cleaved from the resin by using a 
cleavage cocktail reagent ″R″, containing TFA/thioanisole/1,2-ethanedithiol 
(EDT)/anisole (90:5:3:2, v/v/v/v) for 2-3 h. The crude peptides were precipitated and 
washed with cold diethyl ether. To purify the crude peptides, we used a reversed-phase 
high pressure liquid chromatography (RP-HPLC) system using Shimadzu LC-8A 
preparative liquid chromatography on a Phenomenex Gemini C18 column (10 μm, 
250 × 21.2 mm) with a gradient 0-100% of acetonitrile (CH3CN) containing 0.1% 
TFA (v/v) and water containing 0.1% TFA (v/v) for 1 h with a flow rate at 15.0 
mL/min at the wavelength of 214 nm. 
As a representative example, the synthesis of dodecanoyl-[R5] is described here. 
H-Arg(Pbf)-2-chlorotrityl resin (660 mg, 0.35 mmol, 0.53 mmol/g) was swelled in 
DMF for 40 min by N2. Fmoc-Arg(Pbf)-OH (681 mg, 1.05 mmol, 3 equiv) was 
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coupled to the N-terminal of the resin, using HBTU (398 mg, 1.05 mmol, 3 equiv), 
HOBT (142 mg, 1.05 mmol, 3 equiv), and DIPEA (366 µL, 2.1 mmol, 6 equiv) in 
DMF (15 mL) by agitating the resin for 1 h using N2. After the coupling, the resin was 
washed with DMF, followed by Fmoc-deprotection with piperidine in DMF (20%). 
The subsequent three Fmoc-Arg(Pbf)-OH couplings and one Dde-Lys(Fmoc)-OH 
(559 mg, 1.05 mmol, 3 equiv; Dde = 1-(4,4-dimethyl-2,6-dioxocyclohex-1-
ylidene)ethyl) coupling was carried out in the same manner, respectively. After 
removing the Fmoc group in side chain of lysine, dodecanoic acid (210 mg, 1.05 
mmol, 3 equiv) was coupled using HBTU, HOBT, and DIPEA. Then Dde protection 
group at N-terminal of peptide was removed by 2% hydrazine in DMF, followed by 
washing with DMF and DCM. The side chain protected linear peptides were cleaved 
from the resin by using a cleavage cocktail, TFE/acetic acid/DCM (2:1:7, v/v/v) for 1 
h. The filtrate was evaporated, and the residue was dried overnight in a vacuum. The 
cyclization was conducted under a dilute condition with anhydrous DMF/DCM (5:3, 
v/v, 250 mL), using HOAT (190 mg, 1.4 mmol, 4 equiv) and DIC (240 μL, 1.54 
mmol, 4.4 equiv), and stirred for 12 h under nitrogen atmosphere. After cyclization, 
the solvent was evaporated, and the side chain deprotection was carried out by the 
addition of reagent ″R″ for 2 h. The crude dodecanoyl-[R5] was precipitated and 
washed with cold diethyl ether, and purified by preparative RP-HPLC system as 
described above. 
Fluorescein-labeled peptides were synthesized with the same protocol before the 
attachment of fatty acid. We used Fmoc-12-aminododecanoic acid instead of 
dodecanoic acid, and after removing Fmoc group, 5(6)-carboxyfluorescein 
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diisobutyrate (CFDI) was attached using 7-azabenzotriazol-1-yl-
oxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP), HOAT, and DIPEA. 
As an example, we started fluorescein-labeled peptide synthesis in smaller scale with 
H-Arg(Pbf)-2-chlorotrityl resin (208 mg, 0.11 mmol, 0.53 mmol/g). Fmoc-Arg(Pbf)-
OH (214 mg, 0.33 mmol, 3 equiv), Dde-Lys(Fmoc)-OH (176 mg, 0.33 mmol, 3 
equiv), and Fmoc-12-aminododecanoic acid (144 mg, 0.33 mmol, 3 equiv) were used 
to couple each building block to the resin using HBTU (125 mg, 0.33 mmol, 3 equiv), 
HOBT (45 mg, 0.33 mmol, 3 equiv), and DIPEA (115 µL, 0.66 mmol, 6 equiv) in 
DMF. CFDI (170 mg, 0.33 mmol, 3 equiv) was coupled with amino group of 12-
aminododecaonic chain using PyAOP (172 mg, 0.33 mmol, 3 equiv), HOAT (45 mg, 
0.33 mmol, 3 equiv), and DIPEA. The reaction mixture was agitated for 3 h using N2. 
After removal of Dde protecting group with 2% hydrazine in DMF and washing with 
DMF and DCM, side chain protected fluorescein linear peptides were cleaved from 
resin using TFE/acetic acid/DCM (2:1:7, v/v/v). The following cyclization and 
purification steps were same as above. The molecular weights of final products were 
confirmed by an AXIMA performance matrix-assisted laser desorption/ionization-time 
of flight (MALDI-TOF) mass spectrometer (Shimadzu Corporation). 
 
Dodecanoyl-[R5]: MALDI-TOF (m/z): C48H94N22O7 calcd. 1090.7676; found 
1091.7576 [M + H]
+
. Dodecanoyl-[R6]: MALDI-TOF (m/z): C54H106N26O8 calcd. 
1246.8687; found 1247.7397 [M + H]
+
. Dodecanoyl-(R6): MALDI-TOF (m/z): 
C48H96N22O8 calcd. 1108.7781; found 1109.7308 [M + H]
+
. [R5]: MALDI-TOF (m/z): 
C36H72N22O6 calcd. 908.6005; found 909.6772 [M + H]
+
. F′-Dodecanoyl-[R5]: 
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MALDI-TOF (m/z): C69H105N23O13 calcd. 1463.8262; found 1464.6556 [M + H]
+
. F′-
Dodecanoyl-(R5): MALDI-TOF (m/z): C69H107N23O14 calcd. 1481.8368; found 
1482.7586 [M + H]
+
. W-Dodecanoyl-[R5]: MALDI-TOF (m/z): C61H107N25O9 calcd. 
1333.8684; found 1334.8713 [M + H]
+
. W4-[R5]: MALDI-TOF (m/z): C82H114N30O11 
calcd. 1694.9283; found 1696.3111 [M + H]
+
. Octanoyl-[R5]: MALDI-TOF (m/z): 
C44H86N22O7 calcd. 1034.7050; found 1035.7084 [M + H]
+
. Hexadecanoyl-[R5]: 
MALDI-TOF (m/z): C52H102N22O7 calcd. 1146.8302; found 1147.8404 [M + H]
+
. 
 
Cell Culture. Human ovarian adenocarcinoma (SK-OV-3), leukemia (CCRF-CEM), 
and embryonic kidney (HEK 293T) cells were purchased from American Type Culture 
Collection. The SK-OV-3 and HEK 293T cells were grown in eagle’s minimum 
essential medium (EMEM), and RPMI-1640 medium (ATCC, Manassas, VA) was 
used for CCRF-CEM cells. Both medium were supplemented with fetal bovine serum 
(FBS, 10%) and penicillin-streptomycin solution (1%, 10,000 units of penicillin and 
10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2 at 37 °C. 
 
Cytotoxicity Assay. Cytotoxicity of peptides was examined by MTS proliferation 
assay in two human cancer cell lines (SK-OV-3 and CCRF-CEM) and one human 
normal cell line (HEK 293T). Cells were seeded into 96-well plates (SK-OV-3 (5 × 
10
3
 cells/well), CCRF-CEM (1 × 10
5
 cells/well), and HEK 293T (1 × 10
4
 cells/well)). 
Then, the cells were incubated with complete media (100 µL) for overnight. Different 
concentration (0–600 µL) of peptide solution (10 µL) were added to cells and 
incubated at 37 C with 5% CO2 for 24 h. Then, CellTiter 96 aqueous solution (20 µL) 
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was added to each well and incubated for 1-4 h. The absorbance was measured at 490 
nm using microplate reader. The cells without any peptide were used as the control. 
 
Flow Cytometry 
Cellular Uptake of Fluorescein-Labeled Peptide. SK-OV-3 cells were grown in 6-
well plates (2 × 10
5
 cells/well) with complete EMEM media 24 h prior to the 
experiment. The fluorescein-labeled peptide stock solution (1 mM) was prepared in 
water and diluted in Gibco®  Opti-MEM®  I reduced serum medium to obtain the final 
concentration of 5 M. The media were removed and the mixture containing 
fluorescein-labeled peptide solution (5 M) was added. After 1 h incubation, trypsin-
EDTA solution was added to detach cells from plate’s surface and remove cell surface 
binding peptides. After 5 min, the complete media (2 mL) was added to neutralize the 
trypsin. The cells were collected and centrifuged at 2500 rpm for 5 min. Then they 
were washed with PBS (without calcium and magnesium) twice. Samples were 
prepared in FACS buffer for analysis. Finally, the cells were analyzed by BD 
FACSCalibur™ or FACSVerse™ flow cytometer using FITC channel. The data 
collection was based on the mean fluorescence signal for 10,000 cells. All assays were 
carried out in triplicate. 5(6)-Carboxyfluorescein (FAM) was used as a negative 
control. 
 
Mechanism Study of Cellular Uptake by Removing Energy Sources. For 
examination of the cellular uptake mechanism of F′-dodecanoyl-[R5] at low 
temperature, the assay was carried out at 4 °C to inhibit the energy-dependent cellular 
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uptake pathways. The SK-OV-3 cells were preincubated at 4 °C for 15 min and 
incubated with the fluorescein-labeled peptide for 1 h at 4 °C. Cells were collected and 
analyzed using flow cytometry with the previously described protocol above. The data 
collected at 37 °C were used as the control. To perform the ATP-depletion assay, cells 
were incubated with sodium azide (10 mM) and 2-deoxy-D-glucose (50 mM) for 1 h 
before adding the fluorescein-labeled peptide. During the incubation time (1 h), the 
fluorescein-labeled bicyclic peptide (5 M) was prepared in the Opti-MEM®  I 
reduced serum medium in the presence of sodium azide (10 mM) and 2-deoxy- D-
glucose (50 mM). Then, the cells were incubated with this solution for 1 h. The 
following sample preparation and flow cytometry analysis protocol was same as 
described above. 
 
Confocal Laser Scanning Microscopy (CLSM). SK-OV-3 cells were seeded with 
complete EMEM on coverslips in 6-well plate (1 × 10
5
 cells/well) and kept until 50% 
confluency. The media were removed, and cells were incubated with F′-dodecanoyl-
[R5] (10 M) and F′-dodecanoyl-(R5) (10 M) in Gibco®  Opti-MEM®  I reduced 
serum medium (Life Technologies, Grand Island, NY) for 1 h at 37 C. Then cells 
were washed with 1 × phosphate buffered saline with calcium and magnesium (PBS
+
) 
for three times. The coverslips were mounted on microscope slides, and images were 
obtained using Carl Zeiss LSM 700 system with a 488 nm argon ion laser excitation 
and a BP 505-530 nm band pass filter. 
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Intracellular Uptake of a Phosphopeptide, F-GpYEEI. SK-OV-3 and CCRF-CEM 
cells were seeded in 6-well plates (2 × 10
5 
cells/well for SK-OV-3 and 1 × 
10
6
cells/well for CCRF-CEM) and grown with complete EMEM media (RPMI-1640 
for CCRF-CEM) for overnight. A mixture of fluorescein-labeled phosphopeptides F-
GpYEEI (5 M) and peptides (10 M) were prepared in OPTI-MEM I®  reduced 
serum medium at room temperature and incubated for 15 min. Then the cells were 
incubated with the premixed solution at 37 C with 5% CO2 for 1 h. The sample 
preparation for FACS analysis was carried out by previously mentioned protocol 
described before. In this assay, DMSO and F-GpYEEI were used as the negative 
controls. 
 
RESULTS AND DISCUSSION 
Chemistry 
The acylated cyclic polyarginine peptides were synthesized by Fmoc/t-Bu solid-
phase peptide synthesis method. Fmoc-L-Arg(Pbf)-OH was coupled on H-Arg(Pbf) 
loaded 2-chlorotrityl resin in the presence of HBTU, HOBT, and DIPEA in DMF. 
Then Dde-Lys(Fmoc)-OH was attached, and a fatty acid was coupled to the side chain 
of lysine. Dde protecting group was removed by 2% hydrazine in DMF, and a 
cleavage cocktail containing TFE/acetic acid/DCM (2:1:7 v/v/v) was used for 1 h to 
cleave the side-chain protected linear peptides from the resin. Cyclization of linear 
peptides was carried out in the presence of a mixture of HOAT and DIC in anhydrous 
DMF/DCM for 6-24 h. The side-chain deprotection of cyclic peptide were carried out 
by a cleavage cocktail reagent ″R″ for 2 h. The crude peptides were precipitate and 
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purified with RP-HPLC as described above. As a representative example, the synthesis 
of dodecanoyl-[R5] is shown in Scheme 1. 
A corresponding acylated linear polyarginine peptide (ALPP) was synthesized for 
comparative studies with the cyclic peptide (ACPP). Moreover, a cyclic polyarginine 
without fatty acid [R5] was also synthesized to investigate the effect of the fatty acid 
on cyclic peptide and its effect on molecular transporting efficiency. To investigate 
whether the peptide alone can enter into cells, fluorescein-labeled F′-dodecanoyl-[R5], 
and F′-dodecanoyl-(R5), where F = fluorescein, were synthesized for FACS and 
microscopy investigations. All synthesized peptides are shown in Figure 1. 
 
Cytotoxicity Assay of Synthetic Peptides  
The cytotoxicity of all peptides were tested in two different cancer cell lines, 
adherent (SK-OV-3) and non-adherent (CCRF-CEM) cells and a normal cell line 
(HEK 293T) using MTS assay (Figure 2). Cyclic polyarginine [R5] without fatty acid 
was used to explore the effect of N-terminal acylation on cytotoxicity and cellular 
uptake. ALPP (dodecanoyl-(R5)) and [R5] peptides showed consistently less 
cytotoxicity in all three cells compared to ACPPs (dodecanoyl-[R5] and dodecanoyl-
[R6]). After 24 h incubation, ACPPs showed approximately 20% toxicity in cells at a 
concentration of 25 µM in CCRF-CEM cells. However, linear dodecanoyl-(R5) and 
cyclic [R5] did not exhibit significant cytotoxicity at 25 µM and showed less than 20% 
toxicity at the concentration of 100 µM. In SK-OV-3 cells, dodecanoyl-(R5) and [R5] 
showed more than 80% cell viability at the concentration of 25 µM. In normal cells 
(HEK 293T), all peptides exhibited less than 5% toxicity at 25 µM. This differential 
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behavior of the peptides in normal and cancer cells can be possibly rationalized 
through the interaction between polyarginine peptides and cell membranes. The 
membrane of cancer cells holds more negative charges compared to that in normal 
cells because of the presence of anionic lipids such as phosphatidylserine.
10
 Therefore, 
polyarginine peptides can be interacted with cancer cells more effectively compared to 
normal cells. Consequently, higher cell viability was observed in normal cells. These 
data indicated that ACPPs are more toxic than ALPP and a non-acylated cyclic peptide 
[R5], especially at concentration of ≥25 µM.  Thus, a non-cytotoxic concentration of 5-
10 µM was used in cell-based assays. 
 
Cellular Uptake of Fluorescein-labeled Acylated Cyclic and Linear Polyarginine 
Peptides 
The intracellular uptake studies of fluorescein-labeled acylated cyclic and linear 
PP, F′-dodecanoyl-[R5] and F′-dodecanoyl-(R5), was carried out in SK-OV-3 cells by 
using flow cytometry and confocal laser scanning microscopy (CLSM) methods. 
Fluorescein (FAM, F′) alone was selected as a negative control. As it is shown in 
Figure 3, The F-dodecanoyl-[R5] and F-dodecanoyl-(R5) showed approximately 13.7- 
and 10.3-fold higher cellular uptake than that of control 5,6-carboxyfluorescein 
(FAM), respectively, in SK-OV-3 cells. F′-dodecanoyl-[R5] showed 1.3-fold higher 
cellular uptake compared to that of F′-dodecanoyl-(R5). The cellular uptake of F′-
dodecanoyl-[R5] was confirmed by CLSM images (Figure 4). F′-Dodecanoyl-[R5] 
showed higher fluorescence intensity compared to that of F′-dodecanoyl-(R5) in SK-
OV-3 cells. Therefore, ACPP F′-dodecanoyl-[R5] was found to be more efficient cell-
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penetrating peptide compared to the linear counterpart. As shown in Figure 4, the 
fluorescence signal is extended through the whole cells, suggesting that F′-
dodecanoyl-[R5] can get localized in the nucleus as well as cytoplasm. 
 
Cellular Uptake Mechanistic Study of F′-Dodecanoyl-[R5] 
The mechanism of the cellular internalization of F′-dodecanoyl-[R5] was 
investigated by a temperature control assay at 4 °C along with ATP depletion assay. 
These two assays have been widely used to examine the energy-dependent 
endocytosis.
11
 FACS results showed that the intracellular uptake of F′-dodecanoyl-
[R5] was significantly reduced at 4 °C, indicating that the mechanism of 
internalization was mainly dependent on the endocytosis pathways (Figure 5).
12
 
Furthermore, ATP depletion assay was performed to investigate receptor-mediated 
endocytosis.
13
 To induce ATP depletion, SK-OV-3 cells were pre-incubated with 
sodium azide (10 mM) and 2-deoxy-D-glucose (50 mM) for 1 h prior to the 
experiment, and a similar concentration was maintained during the incubation (1 h) 
with F′-dodecanoyl-[R5]. The results showed that the cellular uptake of F′-ACPP was 
inhibited in the presence of sodium azide and 2-deoxy-D-glucose, suggesting that 
receptor-mediated endocytosis is involved for the cellular uptake of F′-ACPP. In ATP 
depletion assay, the basic cellular uptake of FAM was higher compared to that in 
temperature control assay. However, this is evident that the intracellular uptake of F′-
dodecanoyl-[R5] was inhibited, and there was no significant difference between the 
cells treated with FAM compared to those treated with F′-dodecanoyl-[R5] in 
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temperature control and ATP depletion assays, suggesting that endocytosis is the 
major pathway for the cellular uptake of F′-dodecanoyl-[R5].
14
 
 
Molecular Transporter Property of Peptides 
The ability of ACPPs as a molecular transporter was evaluated and compared by 
selecting a fluorescein-labeled phosphopeptide, F′-GpYEEI, as a molecular cargo. The 
phosphopeptide, pYEEI (pTyr-Glu-Glu-Ile) is an optimal peptide template for the SH2 
domain of Src tyrosine kinase. Several analogues of this peptide have been 
synthesized as potent ligands for this target.
15–17
 Due to the presence of the negatively 
charged amino acid residues in the structure of the phosphopeptide including 
phosphorylated tyrosine, it does not cross the cell membrane easily. Moreover, the 
internalization of the negatively charged phosphopeptide in cancer cells by diffusion is 
more difficult because cancer cell membranes are composed of more negatively 
charged lipids. Thus, cellular delivery of cell-impermeable negatively charged 
phosphopeptides is significantly challenging. We have previously reported different 
peptide-based carriers for the intracellular delivery of negatively charged 
phosphopeptides as model cell-impermeable drugs in several cell lines.
18
 
In this study, the intracellular uptake of F′-GpYEEI was monitored in the 
presence and absence of synthetic peptides after 1 h incubation by flow cytometry. As 
it is exhibited in Figure 6, the ACPPs (dodecanoyl-[R5] and dodecanoyl-[R6]) 
delivered the phosphopeptide more efficiently compared to ALPPs, dodecanoyl-(R5) 
and [R5]. The intracellular uptake of F′-GpYEEI in the presence of dodecanoyl-[R5] 
and dodecanoyl-[R6] was enhanced by 3.4- and 5.5-fold higher than the uptake in the 
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absence of ACPPs. However, dodecanoyl-(R5) and [R5] only improved 1.3- and 1.4-
fold intracellular uptake, respectively. The results showed that acylated and cyclized 
polyarginine peptides can deliver the phosphopeptide effectively. However, the 
intracellular uptake of the phosphopeptide did not improve significantly in the 
presence of either acylated linear polyarginine peptide or cyclic [R5]. These data 
suggest that a combination of acylation and cyclization would improve the molecular 
transporting efficiency of the polyarginine-based peptide (containing less than six 
arginines) for the intracellular delivery of a cell-impermeable phosphopeptide. It has 
been previously reported that the acylated linear octa-arginine increased the cellular 
uptake of molecular cargoes by just adding fatty acid to the N-terminal of octa-
arginine.
8
 However, we discovered that both cyclization and acylation in a short penta-
arginine can significantly improve the delivery of a cell-impermeable phosphopeptide 
in SK-OV-3 cells. 
The major driving forces for the intracellular delivery are presumed to be 
structural rigidity through cyclization of the peptide and the interaction of the fatty 
acid with the cell membrane. It has been previously reported that the cellular uptake of 
the peptide can be increased due to the structural rigidity by cyclization of arginine-
rich peptides.
3
 They proposed that the maximal distance between guanidine groups of 
arginine residue can lead to an efficient transduction of arginine-rich peptides. Our 
investigations showed that dodecanoyl-[R6] is able to deliver more efficiently by 1.6-
fold higher F′-GpYEEI uptake compared to that of dodecanoyl-[R5]. Increasing the 
number of positively charged arginine residues can enhance the cellular uptake 
through ionic interactions with the negatively charged phosphopeptide and/or 
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phospholipid in the cell membrane through ionic interactions. However, the higher 
number of arginine residue is not the only responsible element for the efficient cellular 
internalization.  For example, it has been reported that polyarginine containing eleven 
amino acids (R11) showed higher cellular uptake compared to the polyarginine 
containing thirteen amino acids (R13). At the same time, R11 was found to be more 
potent transporter compared to R9 in prostate cancer cells.
19
 These investigations 
showed that an optimal number of arginine residues are required for the highest degree 
of functionality. However, the more number of amino acid residues in cyclic peptides 
can decrease the structural rigidity, which lower the ability of the peptide to get into 
cells. 
Dodecanoyl-[R5] was also compared with several commonly CPPs, such as CR7 
and TAT (YGRKKRRQRRR) peptides. The ACPP improved the cellular uptake of 
the phosphopeptide by 1.4- and 1.8-fold higher than those of CR7 and TAT, 
respectively (Figure 6B). Thus, these results revealed that ACPP dodecanoyl-[R5] can 
be used as an efficient molecular transporter even it has shorter peptide sequence than 
CR7 and TAT. 
 
The Effect of Fatty Acid Chain Length on the Cellular Uptake of ACPPs 
To investigate the effect of the chain length on the cell penetration potency, we 
synthesized octanoyl-[R5], dodecanoyl-[R5], and hexadecanoyl-[R5] (Figure 8). The 
cytotoxicity of the peptides was examined in SK-OV-3 cells. ACPPs showed less than 
20% toxicity in cells at the concentration of 25 µM. The in vitro toxicity results 
showed that increasing the fatty acid chain length caused enhanced toxicity in cells as 
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hexadecanoyl-[R5] was more cytotoxic than dodecanoyl-[R5] and octanoyl-[R5]. These 
data indicate that the fatty acid chain length could alter the interaction with the cell 
membrane and disturb the membrane integrity. Based on the cytotoxicity data, a 
concentration of 10 µM was selected for further cell-based assays. 
It has been previously reported that there was a relationship between the length of 
fatty acid in polyarginines and their cellular uptake,
7
 meaning that the optimal length 
of fatty acid is required for optimal functionality based on the peptide sequence and 
cell type. The results exhibited that the cellular uptake of F′-GpYEEI was improved in 
the order of octanoyl-[R5] < dodecanoyl-[R5] < hexadecanoyl-[R5]. The cellular 
uptake of F′-GpYEEI in the presence of hexadecanoyl-[R5] was 9.3- and 6.0-fold 
higher than that of in the presence of octanoyl-[R5] and dodecanoyl-[R5], respectively. 
These data suggest that among the synthesized peptides, hexadecanoyl-[R5] containing 
a fatty acid with sixteen-carbon chain length (C16) is an optimized length for the 
intracellular delivery of F′-GpYEEI in SK-OV-3 cells. 
 
Effect of Addition of Tryptophan Residues in Molecular Transporter Property  
After ACPPs were found to act as CPP and molecular transporter, a systematic 
investigation was performed to modify the fatty acid to another hydrophobic moiety. 
Two other conjugates were synthesized. In the first conjugate, W4-[R5], the whole 
fatty acid chain was replaced with four tryptophan residues. The second conjugate W-
dodecanoyl-[R5] had one more tryptophan at the end of the dodecanoyl fatty acid 
chain. W4-[R5] enhanced intracellular delivery of F-GpYEEI by 4.1-fold higher 
compared to that of dodecanoyl-[R5] in SK-OV-3. However, W-dodecanoyl-[R5] 
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improved the uptake of F′-GpYEEI by 1.3-fold higher compared to that of W4-[R5] in 
CCRF-CEM cells (Figure 9). The cellular uptake is affected by the cell lines. Thus, it 
is not straightforward to compare the cellular uptakes in SK-OV-3 and CCRF-CEM. 
However, the results could be assessed indirectly by relative comparison with the 
cellular uptake by W4-[R5]. These data suggest that the presence of hydrophobic 
tryptophan moieties could enhance the molecular transporting efficiency. In other 
words, appropriate modification of hydrophobic moiety in CPPs can increase the drug 
delivery ability of ACPP. Existing a balance between the cyclization of short 
polyarginine and the presence of hydrophobic moiety is critical to obtain the optimal 
intracellular transportation ability. 
 
CONCLUSION 
In conclusion, acylated cyclic polyarginine peptides were synthesized and 
examined as CPPs and potential molecular transporters. ACPPs showed higher 
potency as molecular transporter compared to the corresponding linear counterpart and 
cyclic polyarginine without fatty acid. The mechanism of the peptide internalization 
was found to be energy-dependent endocytosis. Cyclization and acylation reactions on 
the structure of the peptide enhanced the intracellular uptake of polyarginine peptides 
although they carry a short length of sequence. This intracellular delivery property of 
ACPPs can be optimized by modifying the length of fatty acid chain. To the best of 
our knowledge, this is the first report of fatty acylated cyclic polyarginine peptide as 
molecular transporter of a cell-impermeable phosphopeptide. This study provided 
insights about how a combination of the cyclic nature and acylation can improve the 
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cell internalization of polyarginines. Further investigations are undergoing to 
determine whether conjugation of cell-impermeable hydrophobic drugs to acylated 
cyclic polyarginines can be an efficient method for designing novel drug delivery 
systems. 
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ABBREVIATIONS 
ACPP, acylated cyclic polyarginine peptides; ALPP, acylated linear polyarginine 
peptide; ATP, adenosine triphosphate; CCRF-CEM, human  leukemia  carcinoma  cell  
line; CFDI, 5(6)-carboxyfluorescein diisobutyrate; CLSM, confocal laser scanning 
microscopy; CPPs, cell-penetrating peptides; DCM,   dichloromethane; Dde, 1-(4,4-
dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl; DIC, N,N-diisopropylcarbodiimide; 
DIPEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide; EDT, 1,2-
ethanedithiol; EMEM, eagle’s minimum essential medium; FAM, 5(6)-
carboxyfluorescein; FBS, fetal bovine serum; Fmoc, 9-fluorenylmethoxycarbonyl; 
FACS, fluorescence activated cell sorter; HBTU, 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate; HEK 293T, human embryonic kidney cell 
line; HOAT, 1-hydroxy-7-azabenzotriazole; HOBT,  hydroxybenzotriazole;  MALDI-
TOF, matrix-assisted laser desorption/ionization-time of flight; MTS, (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium); NMP, N-methylmorpholine); PBS, phosphate buffered saline; PyAOP, 
7-azabenzotriazol-1-yl-oxytris(pyrrolidino)phosphonium hexafluorophosphate; RP-
HPLC, reversed-phase high pressure liquid chromatography; SK-OV-3, human 
ovarian adenocarcinoma cell line; TFA, trifluoroacetic acid; TFE, 2,2,2-
trifluoroethanol ; TIS, triisoproylsilane. 
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Figure legends 
Figure 1: Chemical structures of synthetic peptides used in this study. (F′: fluorescein-
labeled; [  ]: cyclic peptide; (  ): linear peptide) 
Figure 2: Comparison of cytotoxicity between cyclic and linear acylated polyarginine 
peptides, and non-acylated cyclic peptide [R5] at various concentrations against 
CCRF-CEM, SK-OV-3, and HEK 293T after 24 h. 
Figure 3: Comparative cellular uptake of F′-dodecanoyl-[R5] and F′-dodecanoyl-(R5) 
(5 µM) in SK-OV-3 cells (1 h).  
Figure 4: Confocal laser scanning microscope image of (A) F′-dodecanoyl-[R5] and 
(B) F′-dodecanoyl-(R5). The peptides were incubated for 1 h in SK-OV-3 cells at 10 
µM concentration. 
Figure 5: Cellular uptake of F′-dodecanoyl-[R5] (5 µM) in SK-OV-3 cells in 
temperature control assay at 37 °C and 4 °C, and ATP depletion assay with NaN3 (10 
mM) and 2-deoxy-D-glucose (50 mM) analyzed by flow cytometry. 
Figure 6: Cellular uptake of F΄-GpYEEI (5 µM) in the presence of dodecanoyl-[R5], 
[R5], dosecanoyl-(R5), and dodecanoyl-[R6] (10 µM) in SK-OV-3 cell line. 
Phosphopeptide delivery efficiency of dodecanoyl-[R5] were compared with known 
CPPs (R7: CRRRRRRR; TAT: YGRKKRRQRRR). The mean fluorescence of F΄-
GpYEEI taken by dodecanoyl-[R5] was set as 100%. 
Figure 7: Chemical structures of ACPPs with different length of fatty acid chains (C8, 
C12, and C16). 
Figure 8: (A) Cytotoxicity assay of cyclic polyarginine peptide-fatty acid conjugates 
against SK-OV-3 cells (24 h incubation). (B) Cellular uptake of a phosphopeptide, F′-
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GpYEEI (5 μM) in the presence of peptide-fatty acid conjugates (10 μM) in SK-OV-3 
cells. 
Figure 9: Cellular uptake assay of a phosphopeptides, F′-GpYEEI (5 μM) in the 
presence of W4-[R5] and W-dodecanoyl-[R5] (10 μM) against SK-OV-3 and CCRF-
CEM cell lines (1 h incubation). The mean fluorescence of F′-GpYEEI by W4-[R5] 
was set as 100%. 
 
 
Scheme legends 
Scheme 1. Synthesis of dodecanoyl-[R5] as a representative example. 
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ABSTRACT 
Multidrug resistant pathogens have become a major public health concern. There 
is a great need for the development of novel antibiotics with alternative mechanisms of 
action the treatment of life-threatening bacterial infections. Antimicrobial peptides 
(AMPs), a major class of antibacterial agents, share amphiphilicity and cationic 
structural properties with cell-penetrating peptides (CPPs). We have previously 
reported that a number of amphiphilic cyclic peptides have enhanced cellular uptake 
properties in eukaryotic cells versus their linear counterparts. Herein, several 
amphiphilic cyclic CPPs and their analogs were synthesized and exhibited potent 
antibacterial activities against multidrug resistant pathogens. Among them, cyclic 
peptide [R4W4] (peptide 1) showed the most potent antibacterial activity against 
methicillin-resistant Staphylococcus aureus (MRSA, exhibiting a minimum inhibitory 
concentration (MIC) of 2.67 µg/mL). Cyclic [R4W4] and the linear counterpart R4W4 
exhibited MIC values of 42.8 and 21.7 µg/mL, respectively, against Pseudomonas 
aeruginosa. [R4W4] in combination with tetracycline enhanced the potency, by 
decreasing the MIC 4 fold (0.12 µg/mL) presenting partial synergistic effect of the 
combination between peptide 1 and tetracycline against MRSA. Twenty-four hour 
time-kill studies evaluating [R4W4] with 2× the MIC in combination with tetracycline 
demonstrated bactericidal activity at 4 and 8× the MIC of tetracycline against MRSA 
and 2-8× the MIC against E. coli, respectively. Peptide 1 presented its cell-penetrating 
properties as expected, and showed more than 84% cell viability at 15 µM (20.5 
µg/mL) concentration against in three different human cell lines. This study suggests 
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that amphiphilic cyclic CPPs, when used in combination with antimicrobials may 
provide additional benefit to defeat multi-drug resistant pathogens. 
 
Keywords: Antimicrobial Peptide, Cell-Penetrating Peptide, Combination, Drug 
Delivery, MRSA. 
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INTRODUCTION 
The emergence of Methicillin-resistant Staphylococcus aureus (MRSA) threatens 
public health worldwide. Despite a half century of efforts to find effective treatments, 
healthcare practitioners are still challenged to cure infections caused by MRSA.
1
 
MRSA is widespread in hospitals, and community-associated MRSA has continued to 
emerge since the mid-1990s.
2
 In 2009, 463,017 infections were attributed to MRSA, 
which corresponds to 11.74 infections per 1,000 hospitalizations in the United States.
3
 
Approximately 19,000 of human death were attributed to invasive MRSA in 2005.
4
 
Moreover, MRSA rapidly evolves resistance against new commercial antibiotics. 
Currently, vancomycin is employed commonly for the treatment of MRSA. 
However, vancomycin-resistant Staphylococcus aureus was reported in 1996.
5
 
Daptomycin is a cyclic lipopeptide having a broad spectrum against Gram-positive 
bacteria, and it shows fast antibacterial responses. Its novel mechanism of action 
involves membrane depolarization resulting in efflux of potassium ions, followed by 
bacterial cell death.
6
 Despite its novelty of the mechanism, daptomycin-resistance by 
MRSA was reported in 2005, only two years after FDA approval. The resistance 
mechanism against daptomycin remains to be determined.
7
 Thus, new classes of 
antibiotics with different mechanisms of action are urgently needed. 
Antimicrobial peptides (AMPs) have emerged as alternative therapeutics against 
antibiotic resistant pathogens because they can act as effectors and regulators of the 
immune system as well as inhibitors of bacterial cell growth.
8
  Cationic AMPs target 
negatively charged bacterial membrane lipids, which may reduce the occurrence of 
bacterial resistance.
9
 AMPs have been found as host defense peptides in various 
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organisms, such as insects, amphibians, and mammalians.
10,11
 AMPs such as magainin 
and omiganan are in clinical trials or in development.
12
 
Cell-penetrating peptides (CPPs) are short hydrophilic and/or amphiphilic 
peptides. Because of their ability to translocate across the eukaryotic cell membrane, 
they have been studied as molecular vehicles to deliver other drugs inracellularly.
13,14
 
Some AMPs and CPPs share similar physical properties, such as amphiphilicity and 
cationic properties. Thus, CPPs have potential application as AMPs with dual actions 
as both antibiotics and possible molecular transporter properties. 
We have synthesized and evaluated several cyclic CPPs as molecular transporters 
of other cargo drugs. For example, we recently reported that synthetic cyclic peptides 
[WR]4 and [WR]5 enhanced the cellular uptake of phosphopeptides, doxorubicin, and 
anti-HIV drugs.
15
 These peptides are expected to be more stable than linear peptides 
towards human serum because the cyclization decreases proteolytic degradation.
16
 It 
has been previously reported that the rigidity in the peptides can enhance the cell-
penetrating property.
17
 According to our recent study, the acylation and cyclization of 
short polyarginine peptides enhance the intracellular delivery of cell-impermeable 
phosphopeptides. 
In general, AMPs contain hydrophobic and hydrophilic portions that interact with 
the lipid part and hydrophilic negatively charged heads in bacteria membranes, 
respectively. Many linear AMPs adopt amphipathic α-helix conformations with the 
hydrophobic side chains arranged along one side of the helical structure and the 
hydrophilic side chains organized on the opposite side. This arrangement results in the 
ideal amphipathic helical structures.
18
 Some AMPs form amphipathic -sheet 
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conformation to interact with cell membranes.
18
 We hypothesized that amphiphilic 
cyclic peptides with cell-penetrating property can have potential antibacterial and 
synergistic activity with other antibiotics. Herein, we report two classes of amphiphilic 
cyclic CPPs: (a) cyclic peptides containing tryptophan and arginine amino acids and 
(b) fatty acylated cyclic polyarginine peptides (ACPPs). The antimicrobial activities of 
synthesized peptides were evaluated against multidrug-resistant bacterial pathogens. 
 
EXPERIMENTAL SECTION 
Peptide Design and Synthesis. The peptides were synthesized by Fmoc/tBu solid-
phase peptide synthesis. Single amino acid (tryptophan or arginine) preloaded trityl 
resins were employed for the synthesis of cyclic peptides. Fmoc-L-amino acid 
building blocks were coupled to the resin using the 2-(1H−benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), hydroxybenzotriazole (HOBT), 
and N,N-diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF). Fmoc 
protecting groups were removed by treatment with 20% (v/v) piperidine in DMF after 
each coupling. The side chain protected peptides were detached from the resin by 
2,2,2-trifluoroethanol (TFE)/acetic acid/dichloromethane (DCM) (2:1:7, v/v/v), and 
cyclized using 1-hydroxy-7-azabenzotriazole (HOAT), N,N-diisopropylcarbodiimide 
(DIC) in anhydrous DMF/DCM. Then all protecting groups were removed with 
trifluoroacetic acid/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2, v/v/v/v) mixture, 
and crude peptides were collected by precipitation with cold diethyl ether. The crude 
cyclic peptides were purified by a reversed-phase high pressure liquid chromatography 
(RP-HPLC) system using a preparative Phenomenex Gemini C18 column (10 μm, 250 
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× 21.2 mm) with a gradient 0-100% of acetonitrile (CH3CN) containing 0.1% TFA 
(v/v) and water containing 0.1% TFA (v/v) for 1 h with a flow rate of 15.0 mL/min at 
the wavelength of 214 nm. 
As a representative example, the synthesis of peptide 1 ([R4W4]) is described 
here. After swelling of H-Trp(Boc)-2-chlorotrityl resin (449 mg, 0.35 mmol, 0.78 
mmol/g) in DMF for 40 min by N2, three consecutive coupling of Fmoc-Trp(Boc)-OH 
(553 mg, 1.05 mmol, 3 equiv) with the resin was carried out using HBTU (398 mg, 
1.05 mmol, 3 equiv), HOBT (142 mg, 1.05 mmol, 3 equiv), and DIPEA (366 µL, 2.1 
mmol, 6 equiv) in DMF (15 mL). In each coupling step, the mixture of resin and 
reaction solution was agitated using N2 for 1 h. Piperidine in DMF (20% v/v) was used 
to remove Fmoc group after each coupling. The subsequent Fmoc-Arg(Pbf)-OH (681 
mg, 1.05 mmol, 3 equiv) coupling was conducted four times in a similar manner. The 
linear peptide with protected side chain was cleaved from the resin in the presence of 
TFE/acetic acid/DCM (2:1:7, v/v/v) for 1 h. After evaporation and overnight drying of 
the filtrate in a vacuum, the cyclization was carried out under a dilute condition. The 
linear peptide was dissolved in anhydrous DMF/DCM (5:3, v/v, 250 mL). HOAT (190 
mg, 1.4 mmol, 4 equiv), and DIC (240 μL, 1.54 mmol, 4.4 equiv) were added to the 
solution. The reaction mixture was stirred for 12 h under nitrogen atmosphere. Then, 
the solvent was evaporated. Reagent ″R″, trifluoroacetic acid/thioanisole/1,2-
ethanedithiol/anisole (90:5:3:2, v/v/v/v), was added, and the solution was mixed for 2 
h to remove side chain protecting groups. The crude peptide 1 was precipitated and 
washed with cold diethyl ether, and purified by a preparative RP-HPLC system as 
described above. 
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The peptide structures were confirmed by an AXIMA performance matrix-
assisted laser desorption/ionization-time of flight (MALDI-TOF) spectrometer. The 
sequence of synthesized fourteen peptides is shown in Table 1. Fluorescein-labeled 
peptide 1 (F′-[KR4W4]) was synthesized by conjugation of a cyclic peptide (-Ala)-
[KR4W4] and 5(6)-carboxyfluorescein N-hydroxysuccinimide ester in solution phase. 
A cyclic peptide (-Ala)-[KR4W4] was synthesized using the same protocol described 
above but Dde-Lys(Fmoc)-OH was added for attachment of Boc--Ala-OH on the 
side chain of lysine. 
 
[RRRRWWWW] (1): MALDI-TOF (m/z): C68H88N24O8 calcd. 1368.7217; found 
1369.6412 [M + H]
+
. RRRRWWWW-COOH (2): MALDI-TOF (m/z): C68H90N24O9 
calcd. 1386.7323; found 1387.3780 [M + H]
+
. [RRRRWWW] (3): MALDI-TOF 
(m/z): C57H78N22O7 calcd. 1182.6424; found 1183.5685 [M + H]
+
. RRRRWWW-
COOH (4): MALDI-TOF (m/z): C57H80N22O8 calcd. 1200.6529; found 1201.5652 [M 
+ H]
+
. [EEEEWWWW] (5): MALDI-TOF (m/z): C64H68N12O16 calcd. 1260.4876; 
found 1261.3981 [M + H]
+
, 1283.4336 [M + Na]
+
, 1299.4365 [M + K]
+
. 
[EEEEWWW] (6): MALDI-TOF (m/z): C53H58N10O15 calcd. 1074.4083; found 
1075.4027 [M + H]
+
, 1113.4099 [M + K]
+
. [KRRRRR] (7): MALDI-TOF (m/z): 
C36H72N22O6 calcd. 908.6005; found 909.6772 [M + H]
+
. Dodecanoyl-[KRRRRR] 
(8): MALDI-TOF (m/z): C44H86N22O7 calcd. 1034.7050; found 1035.7084 [M + H]
+
. 
Dodecanoyl-[KRRRRR] (9): MALDI-TOF (m/z): C48H94N22O7 calcd. 1090.7676; 
found 1091.7576 [M + H]
+
. Hexadecanoyl-[KRRRRR] (10): MALDI-TOF (m/z): 
C52H102N22O7 calcd. 1146.8302; found 1147.8404 [M + H]
+
. N-Acetyl-L-
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tryptophanyl-12-aminododecanoyl-[KRRRRR] (11): MALDI-TOF (m/z): 
C61H107N25O9 calcd. 1333.8684; found 1334.8713 [M + H]
+
. N-Acetyl-WWWW-
[KRRRRR] (12): MALDI-TOF (m/z): C82H114N30O11 calcd. 1694.9283; found 
1696.3111 [M + H]
+
. Dodecanoyl-[KRRRRRR] (13): MALDI-TOF (m/z): 
C54H106N26O8 calcd. 1246.8687; found 1247.7397 [M + H]
+
. Dodecanoyl-KRRRRR-
COOH (14): MALDI-TOF (m/z): C48H96N22O8 calcd. 1108.7781; found 1109.7308 
[M + H]
+
. 
 
F′-[KR4W4]. Fluorescein-labeled peptide F′-[KR4W4] was synthesized using the same 
protocol, but a lysine residue was added to attach a fluorescein. First, (-Ala)-
[KR4W4] was synthesized in 0.10 mmol scale. H-Trp(Boc)-2-chlorotrityl resin (128 
mg, 0.10 mmol, 0.78 mmol/g), Fmoc-Trp(Boc)-OH (158 mg, 0.30 mmol, 3 equiv), 
Fmoc-Arg(Pbf)-OH (195 mg, 0.30 mmol, 3 equiv), Dde-Lys(Fmoc)-OH (160 mg, 
0.30 mmol, 3 equiv), and Boc--Ala-OH (57 mg, 0.30 mmol, 3 equiv) were used to 
couple each building block to the resin using HBTU (114 mg, 0.30 mmol, 3 equiv), 
HOBT (41 mg, 0.30 mmol, 3 equiv), and DIPEA (105 µL, 0.60 mmol, 6 equiv) in 
DMF. Dde protecting group was removed with 2% hydrazine in DMF, and side chain 
protected linear peptides were cleaved from the resin using TFE/acetic acid/DCM 
(2:1:7, v/v/v). The subsequent cyclization and purification steps were the same as 
described above. 
The (-Ala)-[KR4W4] peptide (8.00 mg, 5.10 µmol) and 5(6)-carboxyfluorescein 
N-hydroxysuccinimide ester (FAM-NHS, 3.14 mg, 6.63 µmol, 1.3 equiv) was coupled 
using PyAOP (3.46 mg, 6.63 µmol, 1.3 equiv), and DIPEA (8.9 µL, 51.0 µmol, 10 
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equiv) in anhydrous DMF (200 µL) and a few drops of anhydrous DCM. The reaction 
mixture was stirred for 3.5 h under N2. After evaporation of the solvent, the residue 
was purified using a preparative RP-HPLC system using the same condition described 
above. After removal of Dde protecting group with 2% hydrazine in DMF and 
washing with DMF and DCM, side chain protected fluorescein linear peptides were 
cleaved from the resin using TFE/acetic acid/DCM (2:1:7, v/v/v). The subsequent 
cyclization and purification steps were described above. F′-[KW4R4]: MALDI-TOF 
(m/z): C98H115N27O16 calcd. 1925.9015; found 1926.8654 [M + H]
+
. 
 
Bacterial Strains. Methicillin-resistant Staphylococcus aureus (MRSA; ATCC 
43300), Pseudomonas aeruginosa (PAO1), and Escherichia coli (ATCC 35218) were 
employed for antimicrobial activities of peptides alone and in the combination with 
tetracycline. 
 
Antibacterial Activities against MRSA and P. aeruginosa. MRSA and P. 
aeruginosa were inoculated into tryptic soy broth (TSB, BD
TM
) at 37 C and shaken at 
175 rpm overnight. The cultured suspension (1 × 10
8
 CFU/mL) was immediately 
diluted into 1 × 10
5
 CFU/mL. All fourteen peptides were dissolved in distilled water 
(except for peptides 5 and 6, dissolved in 50 mM NH4HCO3 solution to increase 
solubility) to make 5 mM solutions, respectively. Tetracycline and tobramycin were 
used as positive control and prepared as 0.10 mg/mL solution and 0.094 mg/mL. 
Minimal inhibitory concentration (MIC) was determined by the two-fold broth 
microdilution method according to National Committee for Clinical Laboratory 
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Standards (NCCLS) guidelines.
19
 Briefly, in a 96-well microtiter plate, all tested 
peptides and control were mixed well with bacteria suspension (1:39, v/v). After a 
series of two-fold dilution, the microtiter plates were then incubated statically at 37 C 
overnight. Absorbance was read at 600 nm by plate reader (SpectraMax M2, 
Molecular Devices). MIC of each peptide was determined as the minimum 
concentration where no visible bacterial growth was present.  Additionally, 
combination activity of peptide 1, 7, 9, 10, and 13 were assessed by mixing with 
tetracycline and bacteria suspension (1:1:38, v/v/v). MICs were determined as the 
same procedures described above. All experiments were triplicated. 
 
Time-Kill Studies. Time-kill studies were performed using MRSA (ATCC 43300) 
and E. coli (ATCC 35218).  Strains were incubated at 37 °C for 18-24 h on tryptic soy 
agar (TSA; Difco, Becton Dickinson Co., Sparks, MD) and a McFarland standard was 
diluted in Mueller Hinton Broth (MHB; Becton Dickinson Co., Sparks, MD) 
supplemented with 25 mg/L calcium and 12.5 mg/L magnesium, to a final 
concentration of ~5.5 log10 CFU/mL.
21
  Peptide 1 ([R4W4]) and tetracycline were 
evaluated at one, two, four, and eight times their respective MICs. Peptide 1 at two 
times the MIC was also combined with tetracycline at one, two, four and eight times 
the MIC to evaluate for synergy, defined as >2 log10 CFU/mL reduction over the most 
active agent alone. Each bacterial-antimicrobial combination was run in triplicate. 
Runs in the absence of antimicrobials ensured adequate growth of the organisms in the 
model. Each culture was incubated in a shaking incubator (Excella E24, New 
Brunswick Scientific, Enfield, CT) at 37°C for an additional 24 h. Samples were taken 
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at 0, 4, and 24 h, serially diluted, and plated on TSA for colony count enumeration, 
where the limit of detection was 2.0 log10 CFU/mL.
21
 Bactericidal activity (99.9% kill) 
was defined as a ≥3 log10 CFU/mL reduction at 24 h in colony count from the initial 
inoculum. Bacteriostatic activity was defined as a <3 log10 CFU/mL reduction. 
 
Cellular Cytotoxicity Assays. MTS proliferation assays were carried out against three 
cell lines (human ovarian adenocarcinoma SK-OV-3, human leukemia CCRF-CEM, 
and human embryonic kidney HEK 293T). Cells were seeded into 96-well plates (5 × 
10
3
 cells for SK-OV-3, 1 × 10
5
 cells for CCRF-CEM, and 1 × 10
4
 cells for HEK 293T) 
and  incubated overnight with 100 L of complete media for overnight at 37 C with 
5% CO2. Various concentrations (0 – 600 M) of the peptide solution (10 L) were 
added to cells. The cells were kept in an incubator (37 C, 5% CO2) for 24 h. Then 
CellTiter 96 aqueous solution (20 L) was added into each well and incubated for 1-4 
h at the same condition. The absorbance was obtained at 490 nm using a microplate 
reader. Wells containing cells in the absence of any peptide were used as control. 
 
Cellular Uptake of Fluorescein-labeled Peptide 1 (F′-[KW4R4]). SK-OV-3 cells 
were grown in 6-well plates (2 × 10
5
 cells/well) with complete EMEM media prior 24 
h to cellular uptake assay. A 1 mM of fluorescein-labeled peptide stock solution was 
prepared in water and diluted in Gibco®  Opti-MEM®  I reduced serum medium to 
prepare a 5 M final concentration. The culture media were removed from 6-well 
plates, and the 5 M fluorescein-labeled peptide solution was added. After 1 h 
incubation, trypsin-EDTA solution was added to detach cells from plate’s surface and 
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remove cell surface binding peptides. After 5 min. treatment with trypsin-EDTA, a 
portion of complete media was added to stop the activity of trypsin. The cell lines 
were collected and centrifuged at 2500 rpm. Then cells were washed twice using PBS 
without calcium and magnesium, and prepared in FACS buffer for cell sorting. The 
cells were analyzed by BD FACSVerse™ flow cytometer using FITC channel. The 
data collection was based on the mean fluorescence signal for 10,000 cells. All assays 
were carried out in triplicate. 5(6)-Carboxyfluorescein (FAM) was used as a negative 
control. 
 
Mechanism Study of Cellular Uptake by Removing Energy Sources. To examine 
the cellular uptake mechanism F′-[KR4W4] at low temperature, the uptake assay was 
carried out at 4 °C to inhibit the energy-dependent cellular uptake. SK-OV-3 cells 
were preincubated at 4 °C for 15 min and then incubated with the fluorescein-labeled 
peptide for 1 h at 4 °C. Cells were collected and assessed with the same protocol 
described in cellular uptake of the fluorescein-labeled peptide. The data collected at 37 
°C were used for control. For the ATP-depletion assay, cells were incubated with 10 
mM sodium azide and 50 mM 2-deoxy-D-glucose for 1 h before adding the 
fluorescein-labeled peptide. During 1 h incubation, the 5 M of F′-[KR4W4] was 
prepared in the Opti-MEM®  I reduced serum medium in the presence of 10 mM 
sodium azide and 50 mM 2-deoxy- D-glucose. Then the cells were incubated with this 
solution for 1 h. The subsequent sample preparation and flow cytometry analysis 
protocol were similar to the protocol described above. 
 
 95 
 
Confocal Laser Scanning Microscopy (CLSM). SK-OV-3 cells were seeded with 
complete EMEM on coverslips in 6-well plate (1 × 10
5
 cells/well) and kept until 50% 
confluency. The media were removed, and cells were incubated with 10 M F′-
[KR4W4] in Gibco®  Opti-MEM®  I reduced serum medium (Life Technologies, Grand 
Island, NY) for 1 h at 37 C. Then cells were washed with 1× phosphate buffered 
saline with calcium and magnesium (PBS
+
) three times. The coverslips were mounted 
on microscope slides, and images were obtained using Carl Zeiss LSM 700 system 
with a 488 nm argon ion laser excitation and a BP 505-530 nm band pass filter. 
 
RESULTS AND DISCUSSION 
Chemistry 
All fourteen peptides 1-14 (Table 1) were synthesized by Fmoc/tBu solid-phase 
peptide synthesis as described above. Peptides 1-6 were synthesized for this study and 
peptides 7-14 have already been reported in Manuscript II for cellular uptake. Peptides 
1-4 were designed to have positive charge and hydrophobic moieties. On the other 
hand, peptides 5 and 6 were designed to have negative charge and hydrophobic 
moieties for comparative studies. Peptides 7-13 have cyclic polyarginines and 
hydrophobic fatty acids or tryptophan. Peptide 14 was synthesized as linear 
counterpart of peptide 13. The chemical structures of synthesized peptides are shown 
in Figure 1. 
As a representative example, the synthesis of [R4W4] is described here (Scheme 
1). Fmoc-Trp(Boc)-OH was coupled on H-Trp(Boc)-2-chlorotrityl resin three times 
using HBTU, HOBT, and DIPEA in DMF. Piperidine in DMF (20% v/v) was used to 
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remove Fmoc group after each coupling. The subsequent coupling of Fmoc-Arg(pbf)-
OH was conducted four times in a similar manner. The linear peptide with protected 
side chain was cleaved from the resin using TFE/acetic acid/DCM (2:1:7, v/v/v) and 
cyclized in the presence of HOAT and DIC. Reagent ″R″, trifluoroacetic 
acid/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v), was added to remove side 
chain protecting groups to yield crude peptide 1. The peptide was purified by a 
preparative RP-HPLC system as described in the experimental section. 
 
Antibacterial Activities 
MIC and IC50 values were measured for the fourteen peptides against MRSA and 
P. aeruginosa (Table 2). These two bacterial strains are the representative strains of 
Gram-positive and Gram-negative pathogens. MRSA is the most common Gram-
positive pathogen that causes life-threatening infection, while Pseudomonas 
aeruginosa is a Gram-negative multi-drug resistant pathogen which can use multidrug 
efflux pumps and gene mutations.
22
 Overall, these peptides were more potent against 
the Gram-positive MRSA than the Gram-negative P. aeruginosa. The lowest MIC 
values against P. aeruginosa was 21.7 µg/mL (15.6 µM) of peptide 2 while other 
compounds showed MICs more than 37.0 µg/mL (31.3 µM). Peptide 1 was the most 
potent peptide against MRSA with a MIC value 2.67 µg/mL (1.95 µM). Cyclic 
peptides 1, 3, 9, 10, and 13 showed better antibacterial activities compared to linear 
peptides 2, 4, and 14. Acylated cyclic peptides 9, 10, and 13 exhibited more potent 
activity than the non-acylated cyclic peptide 7. These data are consistent with the cell-
penetrating property of amphiphilic peptides described in Manuscript II. The 
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correlation between antimicrobial activity and cell-penetrating property is presumably 
due to the interaction between positively charged amphiphilc peptides and bacterial 
membranes that have negatively charged components. These data explain why 
negatively charged peptides 5 and 6 did not show any antibacterial activities. Peptide 1 
showed promising results as an antimicrobial peptide against MRSA. Thus, it was 
selected for further synergistic studies. 
 
Combination effect of peptides and tetracycline against MRSA 
Based on antibacterial activity screening, peptides 1, 9, 10, and 13 were selected 
to determine whether they could increase the antibacterial activity when co-incubated 
with tetracycline. Non-acylated cyclic peptide 7 was used as a control since it showed 
the lowest potency and was structurally different from other cyclic peptides. Peptide 1 
in combination with tetracycline showed the most potent antibacterial activity with a 
MIC value of 0.12 µg/mL against MRSA (Table 3). Peptides 9, 10, and 13 exhibited 
MIC values of 0.19-0.22 µg/mL. Among all peptides, control non-acylated peptide 7 
exhibited the lowest potency (MIC = 0.31 µg/mL). 
Fraction inhibitory concentration (FIC) index has been widely used to examine 
the interaction between two antibiotics.
23
 When drug A and drug B are applied in 
combination, FIC index can be calculated by the equation ‘FIC index = MIC (A in 
combination with B)/MIC (A alone) + MIC (B in combination with A)/ MIC (B 
alone)’.24,25  The FIC index values are interpreted as ‘synergy’ with FIC ≤ 0.5, ‘partial 
synergy’ with FIC between 0.5 and 1, ‘indifference’ with FIC 1-4, and ‘antagonism’ 
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with FIC > 4.
23,26,27
 According to this definition, the combination of peptide 1 and 
tetracycline can be defined as partial synergy (Table 3). 
 
Time-kill Studies against MRSA and E. coli 
Time-kill studies were conducted to evaluate the antimicrobial activity of peptide 
1 alone and in combination with tetracycline against MRSA and E. coli over 24 h. 
Peptide 1 and tetracycline alone did not demonstrate bactericidal (>3 log10 CFU/mL 
reduction) activity against MRSA. Combinations of two times the MIC of peptide 1 
with four and eight times the MIC of tetracycline demonstrated bactericidal activity 
against MRSA by 24 h. Thus, combinations of peptide 1 and tetracycline did not meet 
the definition for synergy against MRSA. However, the combination of the two 
compounds turned the bacteriostatic activities of tetracycline and peptide 1 into the 
bactericidal activity. 
Peptide 1 alone was able to produce bactericidal activity alone against E. coli 
only at the highest concentration tested (8× the MIC). All combinations of peptide 1 
and tetracycline demonstrated bactericidal activity at 24 h. The combination of eight 
times the MIC of tetracycline and 2× the MIC of peptide 1 also demonstrated synergy 
at 24 h. More studies are required to determine the mechanism of synergism. One 
assumption is that amphiphilic peptide 1 acts as cell-penetrating peptide and can 
deliver tetracycline at higher concentration. The fluorescence studies using peptide 1 
and tetracycline were challenging because emission and excitation range for 
tetracycline were outside the range determined by the flow cytometer. 
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Cytotoxicity Assay of Peptide 1 
The cytotoxicity of peptide 1 was evaluated by MTS proliferation assay against 
human ovarian adenocarcinoma SK-OV-3, human leukemia CCRF-CEM, and human 
embryonic kidney HEK 293T cell lines. In both cancer and normal cell lines, the 
compound showed more than 84% cell viability at 15 µM (20.5 µg/mL) concentration 
(Figure 3). Peptide 1 alone showed 2.67 µg/mL MIC against MRSA that is 
significantly lower than the cytotoxic concentration of peptide 1. Furthermore, the 
therapeutic index peptide 1 was increased when was combined with tetracycline 
showing a MIC value of 0.12 µg/mL, exhibiting partial synergistic effect. Therefore, 
the combination of peptide 1 with tetracycline can be used to enhance the therapeutic 
index. 
 
Cell-Penetrating Property of Peptide 1 ([R4W4]) 
Peptide 1 was originally designed as a CPP to have cell-penetrating property. 
Thus, we synthesized fluorescein-labeled peptide 1 (F′-[KR4W4]) for cellular uptake 
assays, where F is fluorescein. The fluorescein-labeled peptide, F′-[KR4W4] (10 M) 
was added to SK-OV-3 cells and incubated for 1 h at 37 C. Confocal laser scanning 
microscope (CLSM) images showed that the fluorescein-labeled peptide was dispersed 
into the nucleus and cytosol (Figure 4), but no significant fluorescence was observed 
in the cells treated with fluorescein alone under the similar condition (data not shown). 
The mechanism of cellular uptake was investigated by a temperature control 
assay at 4 °C and ATP depletion assay. The cellular uptake of peptide 1 was decreased 
about 59% at 4 °C, indicating that the cellular uptake occurred by both endocytotic 
 100 
 
and nonendocytotic pathways (Figure 5). ATP depletion assay also supports this 
mixed pathways because there was 80% intracellular transportation even though all 
energy source was blocked by sodium azide and 2-deoxy-D-glucose. These results 
were consistent with the previous studies that indicated that intracellular transportation 
can be controlled by several mixed pathways.
28
 
 
CONCLUSION 
Amphiphilic cyclic CPPs (peptides 1, 9, 10, and 13) exhibited potent antibacterial 
activities against Gram-positive MRSA in the range of 2.67–9.75 µg/mL. Cyclic 
peptides showed better antibacterial activities compared to the corresponding linear 
counterparts. Fatty acylated cyclic peptides exhibited more potency versus non-
acylated cyclic peptide. The antibacterial activity correlates well with cell-penetrating 
property of the same peptides. These data suggest that amphiphilic cyclic CPPs with 
improved cellular uptake leads to more potent antibacterial activity. Moreover, we 
found the combination of amphiphilic cyclic CPPs with tetracycline can be partially 
synergistic and thus may be more effective in the treatment of multidrug-resistant 
pathogens. Time-kill study showed both peptide 1 and tetracycline had bacteriostatic 
activities for MRSA and E. coli. However, the combination of those two compounds 
exhibited bactericidal activities in both pathogens. The data provide insights in 
exploring the combination of amphiphilic cyclic peptides with other antibiotics. This 
study suggests that amphiphilic cyclic CPPs could provide alternative strategy in 
defeating life-threatening infectious diseases. 
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ABBREVIATIONS 
AMPs, antimicrobial peptides; ACPPs, acylated cyclic polyarginine peptides; 
ATP, adenosine triphosphate; Boc, tert-Butoxycarbonyl; CCRF-CEM, human  
leukemia  carcinoma  cell  line; CFU, colony-forming unit; CLSM, confocal laser 
scanning microscopy; CPPs, cell-penetrating peptides; DCM,   dichloromethane; Dde, 
1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl; DIC, N,N-
diisopropylcarbodiimide; DIPEA, N,N-diisopropylethylamine; DMF, N,N-
dimethylformamide; EDT, 1,2-ethanedithiol; EDTA, ethylenediaminetetraacetic acid; 
EMEM, eagle’s minimum essential medium; FAM, 5(6)-carboxyfluorescein; FAM-
NHS, 5(6)-carboxyfluorescein N-hydroxysuccinimide ester; FBS, fetal bovine serum; 
Fmoc, 9-fluorenylmethoxycarbonyl; FACS, fluorescence activated cell sorter; HBTU, 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HEK 
293T, human embryonic kidney cell line; HOAT, 1-hydroxy-7-azabenzotriazole; HIV, 
human immunodeficiency virus; HOBT,  hydroxybenzotriazole;  MALDI-TOF, 
matrix-assisted laser desorption/ionization-time of flight; MHB, Mueller Hinton 
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Broth; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant 
Staphylococcus aureus; MTS, (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); Pbf, 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl; PBS, phosphate buffered saline; PyAOP, 
7-azabenzotriazol-1-yl-oxytris(pyrrolidino)phosphonium hexafluorophosphate; RP-
HPLC, reversed-phase high pressure liquid chromatography; SK-OV-3, human 
ovarian adenocarcinoma cell line; TFA, trifluoroacetic acid; TFE, 2,2,2-
trifluoroethanol; TIS, triisoproylsilane; TSB, tryptic soy broth. 
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Table legends 
Table 1: Synthetized peptides list used for antimicrobial activity  
Table 2: Antibacterial activities of synthetic peptides against Gram-positive and 
Gram-negative strains 
Table 3: Antimicrobial activity of peptides in combination with tetracycline against 
MRSA 
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Figure legends 
Figure 1: Chemical structures of synthetic peptides examined for antimicrobial 
activity 
Figure 2: Time-kill curves of peptide 1, tetracycline, and combination for MRSA 
(ATCC 43300) and E. coli (ATCC 35218) at 37 °C for 24 h. Peptide 1 at two times the 
MIC was combined with tetracycline at one, two, four and eight times (MICs of 
peptide 1: 4 µg/mL for MRSA and 16 µg/mL for E. coli; tetracycline (TC): 0.5 µg/mL 
for MRSA and 2 µg/mL for E. coli). 
Figure 3: Cytotoxicity assay of peptide 1 by MTS-PMS assay (24 h incubation) 
Figure 4: Confocal laser scanning microscope image of F′-[KR4W4] (10 µM) in SK-
OV-3 cells (1 h incubation). 
Figure 5: Energy-dependent mechanistic study of intracellular uptake for F′-[KW4R4]. 
Cellular uptake was investigated under 4 C and ATP depletion conditions. 
 
Scheme legends 
Scheme 1: The synthesis of peptide 1 ([R4W4]) 
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Table 1 
Peptide 
No. 
Peptide sequence Abbreviation 
1 [RRRRWWWW] [R4W4] 
2 RRRRWWWW-COOH R4W4 
3 [RRRRWWW] [R4W3] 
4 RRRRWWW-COOH R4W3 
5 [EEEEWWWW] [E4W4] 
6 [EEEEWWW] [E4W3] 
7 [KRRRRR] [KR5] 
8 Octanoyl-[KRRRRR] C8-[R5] 
9 Dodecanoyl-[KRRRRR] C12-[R5] 
10 Hexadecanoyl-[KRRRRR] C16-[R5] 
11 N-Acetyl-L-tryptophanyl-12-aminododecanoyl-[KRRRRR] W-C12-[R5] 
12 N-Acetyl-WWWW-[KRRRRR] W4-[R5] 
13 Dodecanoyl-[KRRRRRR] C12-[R6] 
14 Dodecanoyl-KRRRRR-COOH C12-(R5) 
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Table 2 
Peptide 
No. 
Methicillin-resistant  
Staphylococcus aureus 
Pseudomonas aeruginosa 
MIC (µg/mL)
a
 IC50 (µM) ± SD
b
 MIC (µg/mL) IC50 (µM) ± SD 
1 2.67 (1.95) NA 42.8 (31.3) 3.1 ± 0.7 
2 43.4 (31.3) 16.3 ± 1.7 21.7 (15.6) 9.6 ± 1.2 
3 18.5 (15.6) 10.3 ± 1.0 37.0 (31.3) 9.8 ± 2.7 
4 150 (125) 82.5 ± 30.9 150 (125) 33.1 ± 3.1 
5 >158 (>125) NA >158 (>125) NA 
6 >134 (>125) NA >134 (>125) NA 
7 >114 (>125) NA >114 (>125) NA 
8 129 (125) 81.1 ± 2.9 >129 (>125) NA 
9 8.53 (7.81) 4.4 ± 0.3 136 (125) 41.0 ± 6.2 
10 8.97 (7.81) 4.7 ± 1.6 >143 (>125) NA 
11 83.4 (62.5) 26.2 ± 10.0 167 (125) 44.0 ± 3.9 
12 53.0 (31.3) 19.5 ± 3.5 >212 (>125) NA 
13 9.75 (7.81) 3.9 ± 0.02 156 (125) 45.3 ± 5.6 
14 69.3 (62.5) 27.7 ± 3.0 >139(>125) NA 
Control
c
 0.156 (0.352) 0.13 ± 0.01 0.731 (1.56) NA 
a
Value in parenthesis presents MIC in micromolar concentration;
 b
Data are presented 
as means ± standard deviation where applicable; 
c
Tetracycline and tobramycin were 
used as control for MRSA and P. aeruginosa, respectively. 
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Table 3 
Compounds MIC (µg/mL) IC50 (µM) ± SD
a
 FIC index
b
 
1 + TC
c
 0.12 0.08 0.8 
7 + TC 0.31 0.11 ± 0.01 NA 
9 + TC 0.20 0.10 ± 0.01 1.2 
10 + TC 0.22 0.13 ± 0.04 1.3 
13 + TC 0.19 0.13 ± 0.02 1.4 
TC
 
0.15 0.15 ± 0.02 - 
a
Data are presented as means ± standard deviation where applicable
; b
Fraction 
inhibitory concentration (FIC) index = MIC (A in combination with B)/MIC (A alone) 
+ MIC (B in combination with A)/MIC (B alone). Synergy: FIC ≤ 0.5; partial synergy: 
0.5 < FIC ≤ 1; indifference: 1 < FIC ≤ 4; antagonism: FIC > 4; cTC stands for 
tetracycline. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Scheme 1 
 
 
 
